US20060094715A1 - 5-Ht4 receptor antagonists for the treatment of heart failure - Google Patents
5-Ht4 receptor antagonists for the treatment of heart failure Download PDFInfo
- Publication number
- US20060094715A1 US20060094715A1 US10/514,386 US51438605A US2006094715A1 US 20060094715 A1 US20060094715 A1 US 20060094715A1 US 51438605 A US51438605 A US 51438605A US 2006094715 A1 US2006094715 A1 US 2006094715A1
- Authority
- US
- United States
- Prior art keywords
- heart failure
- methyl
- amino
- receptor antagonist
- piperidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 158
- 238000011282 treatment Methods 0.000 title claims description 46
- 229940044551 receptor antagonist Drugs 0.000 title abstract description 20
- 239000002464 receptor antagonist Substances 0.000 title abstract description 20
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 49
- 239000003523 serotonin 4 antagonist Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 40
- 206010007558 Cardiac failure chronic Diseases 0.000 claims abstract description 20
- 230000001684 chronic effect Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 217
- 230000004044 response Effects 0.000 claims description 128
- 230000000297 inotrophic effect Effects 0.000 claims description 105
- 210000002216 heart Anatomy 0.000 claims description 63
- MOZPSIXKYJUTKI-UHFFFAOYSA-N GR 113808 Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 MOZPSIXKYJUTKI-UHFFFAOYSA-N 0.000 claims description 38
- 230000001965 increasing effect Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 24
- 230000002861 ventricular Effects 0.000 claims description 24
- 230000004217 heart function Effects 0.000 claims description 20
- 206010061216 Infarction Diseases 0.000 claims description 19
- -1 benzoate amides Chemical class 0.000 claims description 19
- 230000006872 improvement Effects 0.000 claims description 19
- 230000000747 cardiac effect Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000002876 beta blocker Substances 0.000 claims description 10
- 229940097320 beta blocking agent Drugs 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010071436 Systolic dysfunction Diseases 0.000 claims description 7
- 230000001771 impaired effect Effects 0.000 claims description 7
- AOOSJYIINXVNHV-UHFFFAOYSA-N (1-butylpiperidin-4-yl)methyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate Chemical compound C1CN(CCCC)CCC1COC(=O)C1=CC(Cl)=C(N)C2=C1OCCO2 AOOSJYIINXVNHV-UHFFFAOYSA-N 0.000 claims description 6
- FCKKCDRMGKXQDK-UHFFFAOYSA-N (1-butylpiperidin-4-yl)methyl 5-amino-6-iodo-2,3-dihydro-1,4-benzodioxine-8-carboxylate Chemical compound C1CN(CCCC)CCC1COC(=O)C1=CC(I)=C(N)C2=C1OCCO2 FCKKCDRMGKXQDK-UHFFFAOYSA-N 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- QSMYZGMJSGUWPM-UHFFFAOYSA-N RS 39604 hydrochloride Chemical compound Cl.COC1=CC(OC)=CC(COC=2C(=CC(Cl)=C(N)C=2)C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)=C1 QSMYZGMJSGUWPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- KVCSJPATKXABRQ-UHFFFAOYSA-N piboserod Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KVCSJPATKXABRQ-UHFFFAOYSA-N 0.000 claims description 5
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 4
- QLZLBYYNMGQIAR-UHFFFAOYSA-N hydron;3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate;chloride Chemical compound Cl.COC1=CC(N)=C(Cl)C=C1C(=O)OCCCN1CCCCC1 QLZLBYYNMGQIAR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- MXZAMPPIKDHMOJ-UHFFFAOYSA-N (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 6-methoxy-2-oxo-3h-benzimidazole-1-carboxylate;hydrochloride Chemical compound Cl.C1C(N2C)CCC2CC1OC(=O)N1C(=O)NC2=CC=C(OC)C=C21 MXZAMPPIKDHMOJ-UHFFFAOYSA-N 0.000 claims description 3
- KMWKEUFOLNYSOV-UHFFFAOYSA-N 1-(1-piperidin-1-ylethyl)indole-3-carboxylic acid Chemical compound C1=C(C(O)=O)C2=CC=CC=C2N1C(C)N1CCCCC1 KMWKEUFOLNYSOV-UHFFFAOYSA-N 0.000 claims description 3
- QIJDKJDKIXUMBB-UHFFFAOYSA-N 1h-indazole-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)N)=NNC2=C1 QIJDKJDKIXUMBB-UHFFFAOYSA-N 0.000 claims description 3
- FFNWMBDISAYHDC-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid 2-(diethylamino)ethyl ester Chemical compound CCN(CC)CCOC(=O)C1=CC(Cl)=C(N)C=C1OC FFNWMBDISAYHDC-UHFFFAOYSA-N 0.000 claims description 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims description 3
- PDHQWITZFXEYGY-UHFFFAOYSA-N 5-fluoro-1-[2-(methanesulfonamido)ethyl]-2-methoxy-6-methyl-4-piperidin-1-ylindole-3-carboxylic acid Chemical compound FC1=C(C)C=C2N(CCNS(C)(=O)=O)C(OC)=C(C(O)=O)C2=C1N1CCCCC1 PDHQWITZFXEYGY-UHFFFAOYSA-N 0.000 claims description 3
- SKYGATVDBNOBSE-FZMZJTMJSA-N 6-chloro-n-[[(1s,8s)-2,3,5,6,7,8-hexahydro-1h-pyrrolizin-1-yl]methyl]imidazo[1,2-a]pyridine-8-carboxamide Chemical compound C12=NC=CN2C=C(Cl)C=C1C(=O)NC[C@H]1[C@@H]2CCCN2CC1 SKYGATVDBNOBSE-FZMZJTMJSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 3
- SSPCCAYAIDNNJX-UHFFFAOYSA-N [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 5-fluoro-2-methoxy-1h-indole-3-carboxylate Chemical compound COC=1NC2=CC=C(F)C=C2C=1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 SSPCCAYAIDNNJX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 3
- 150000002475 indoles Chemical class 0.000 claims description 3
- QEZYDSSGVBTNBH-UHFFFAOYSA-N n-[2-[4-(adamantane-1-carbonylamino)piperidin-1-yl]ethyl]-1-propan-2-ylindazole-3-carboxamide Chemical compound C12=CC=CC=C2N(C(C)C)N=C1C(=O)NCCN1CCC(NC(=O)C23CC4CC(CC(C4)C2)C3)CC1 QEZYDSSGVBTNBH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical class OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229940124975 inotropic drug Drugs 0.000 claims description 2
- 230000035488 systolic blood pressure Effects 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- QXAUTQFAWKKNLM-UHFFFAOYSA-N methyl indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CNC2=C1 QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 claims 4
- BUEFUOFMOXJXAR-TXEJJXNPSA-N 2-[(3r,5s)-3,5-dimethylpiperidin-1-yl]ethyl 4-amino-5-chloro-2-methoxybenzoate Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)OCCN1C[C@H](C)C[C@H](C)C1 BUEFUOFMOXJXAR-TXEJJXNPSA-N 0.000 claims 2
- RLSGBCUXLRMTPF-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxybenzoic acid 3-(1-piperidinyl)propyl ester Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)OCCCN1CCCCC1 RLSGBCUXLRMTPF-UHFFFAOYSA-N 0.000 claims 2
- HJGMRAKQWLKWMH-UHFFFAOYSA-N 8-methyl-8-azabicyclo[3.2.1]octan-3-amine Chemical compound C1C(N)CC2CCC1N2C HJGMRAKQWLKWMH-UHFFFAOYSA-N 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- VUVGMQNYJPPCCC-UHFFFAOYSA-N pyrido[1,2-a]indole Chemical compound C1=CC=CC2=CC3=CC=CC=C3N21 VUVGMQNYJPPCCC-UHFFFAOYSA-N 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 17
- 208000019622 heart disease Diseases 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 229940076279 serotonin Drugs 0.000 description 82
- 102000005962 receptors Human genes 0.000 description 73
- 108020003175 receptors Proteins 0.000 description 73
- 241000700159 Rattus Species 0.000 description 48
- 210000003540 papillary muscle Anatomy 0.000 description 44
- 230000001404 mediated effect Effects 0.000 description 23
- 239000000556 agonist Substances 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 21
- 239000005557 antagonist Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 17
- 208000010125 myocardial infarction Diseases 0.000 description 16
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 14
- 229960005417 ketanserin Drugs 0.000 description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000008101 lactose Substances 0.000 description 13
- 210000004165 myocardium Anatomy 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000007574 infarction Effects 0.000 description 12
- 229940039009 isoproterenol Drugs 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 10
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 10
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 10
- 229930003347 Atropine Natural products 0.000 description 10
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 10
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 10
- 229960000396 atropine Drugs 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 9
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 229960004605 timolol Drugs 0.000 description 9
- VPJXQGSRWJZDOB-UHFFFAOYSA-O 2-carbamoyloxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(N)=O VPJXQGSRWJZDOB-UHFFFAOYSA-O 0.000 description 8
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229960004484 carbachol Drugs 0.000 description 7
- 210000005240 left ventricle Anatomy 0.000 description 7
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 7
- 229960001289 prazosin Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000001688 serotonin response Effects 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000001447 compensatory effect Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 210000002837 heart atrium Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229960001317 isoprenaline Drugs 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 208000020446 Cardiac disease Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001800 adrenalinergic effect Effects 0.000 description 4
- 238000001949 anaesthesia Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 4
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JWZZKOKVBUJMES-NSHDSACASA-N L-isoprenaline Chemical compound CC(C)NC[C@H](O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-NSHDSACASA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003295 lusitropic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000003551 muscarinic effect Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960000309 enalapril maleate Drugs 0.000 description 2
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000001435 haemodynamic effect Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960001300 metoprolol tartrate Drugs 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MMCOFFGHTULVNH-UHFFFAOYSA-N (1-butylpiperidin-4-yl)methyl 2,3-dihydro-1,4-benzodioxine-5-carboxylate hydrochloride Chemical compound Cl.C1CN(CCCC)CCC1COC(=O)C1=CC=CC2=C1OCCO2 MMCOFFGHTULVNH-UHFFFAOYSA-N 0.000 description 1
- YEQGKAOSYSXEPU-UHFFFAOYSA-N (1-butylpiperidin-4-yl)methyl 5-amino-6-chloro-2,3-dihydro-1,4-benzodioxine-8-carboxylate;hydron;chloride Chemical compound Cl.C1CN(CCCC)CCC1COC(=O)C1=CC(Cl)=C(N)C2=C1OCCO2 YEQGKAOSYSXEPU-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UVOCSZKGWJOKNN-UHFFFAOYSA-N 1-(5-amino-6-chloro-2,3-dihydro-1,4-benzodioxin-8-yl)-3-[1-[3-(3,4-dimethoxyphenyl)propyl]piperidin-4-yl]propan-1-one Chemical compound C1=C(OC)C(OC)=CC=C1CCCN1CCC(CCC(=O)C=2C=3OCCOC=3C(N)=C(Cl)C=2)CC1 UVOCSZKGWJOKNN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KMTLTEVOQLMYRS-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1h-quinazoline-2,4-dione Chemical compound OC(=O)C(O)C(O)C(O)=O.C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 KMTLTEVOQLMYRS-UHFFFAOYSA-N 0.000 description 1
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical class CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031383 Fibulin-7 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000846874 Homo sapiens Fibulin-7 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- MDIGAZPGKJFIAH-UHFFFAOYSA-N Serotonin hydrochloride Chemical compound Cl.C1=C(O)C=C2C(CCN)=CNC2=C1 MDIGAZPGKJFIAH-UHFFFAOYSA-N 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 208000028925 conduction system disease Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ABFMKNAYGAIHHX-UHFFFAOYSA-N ethyl 4-amino-5-chloro-2-methoxybenzoate Chemical compound CCOC(=O)C1=CC(Cl)=C(N)C=C1OC ABFMKNAYGAIHHX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- FVJYRSBRURPRLK-UHFFFAOYSA-N n-[(1-butylpiperidin-4-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide;hydrochloride Chemical compound Cl.C1CN(CCCC)CCC1CNC(=O)C1=CC=CC2=C1OCCO2 FVJYRSBRURPRLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940097271 other diuretics in atc Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to heart failure and in particular the use of 5-HT 4 receptor antagonists for the treatment of heart failure and the symptoms associated therewith.
- Heart failure is a disease that primarily affects the elderly and with a population which is ageing progressively it is likely that the prevalence of this disease will continue to increase. New and improved methods of treating heart failure are therefore required.
- Heart disorders or diseases which are generally characterised by impaired cardiac function, e.g. heart failure, affect a large number of people worldwide and in particular in the Western world. Heart disorders or diseases are responsible for a reduced quality of life and premature death in a significant proportion of sufferers. Heart disorders occur in men, women, and children of both sexes, but are particularly prevalent in men and in elderly or middle aged people.
- Heart failure is characterized by impaired cardiac function either due to reduced pump function (systolic dysfunction) or reduced filling (diastolic dysfunction).
- systolic dysfunction reduced pump function
- diastolic dysfunction reduced filling
- cardiomyopathy primary or secondary
- hypertension hypertension
- valvular diseases congenital defects.
- Ischemic heart disease (or ischemic cardiomyopathy) is the major etiologic group of heart failure in the Western world.
- a reduced blood supply to the heart can manifest itself as angina pectoris (pain in the chest), acute myocardial infarction (which is the result of acute coronary artery occlusion causing a damaged myocardium with scar tissue; such an area cannot sustain cardiac muscle function), and sudden deaths. If the blood supply to the heart is reduced over periods of weeks to years, or if the myocardium has been substantially weakened by infarction with scar tissue, the heart function will become weakened with reduced pumping ability leading to the clinical manifestation of chronic heart failure.
- Congestive heart failure (CHF, of which chronic congestive heart failure (cCHF) is a subset), is characterised by impaired left ventricular function, increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and dyspnea. Circulatory congestion results from the decrease in cardiac output or from the damming of blood in the veins behind the left or right heart.
- CHF chronic congestive heart failure
- angiotensin converting enzyme (ACE) inhibitors slow the progression of heart failure by inhibiting the formation of angiotensin and causing vasodilation.
- ACE angiotensin converting enzyme
- diuretics are also common, which relieve water retention in the body thus easing the workload on the heart.
- Digitalis preparations such as digoxin are also used to increase the force of the heart's contractions.
- Betablockers are another commonly used treatment for heart failure, alone or in combination with ACE inhibitors.
- the failing heart is adrenergically activated, in contrast to the normally functioning human ventricle when in a resting state (Bristow, 2000, Circulation, Vol 101, 558-569).
- the increase in cardiac adrenergic drive appears to be damaging to the failing heart and is thus termed a maladaptive response.
- This response appears to be associated with changes in the composition of the adrenoceptors during heart failure with up-regulation of ⁇ 1 adrenoceptors and the down-regulation of ⁇ adrenoceptors.
- mouse models overexpressing activated adrenoceptors show cardiomyopathy and systolic dysfunction. Chronic adrenergic signalling is therefore considered to be a harmful compensatory mechanism in the failing human heart.
- Blockade of the remaining signalling capacity using betablockers complements the heart's endogenous antiadrenergic strategy of desensitisation, which is considered to be an adaptive change (Bristow, 2000, Circulation, Vol 101, 558-569).
- ⁇ blocker treatment is not successful for all patients as some patients show contraindications to ⁇ blockade such as reactive airways disease, sinus node or conduction system disease with bradycardia. Furthermore the target doses require careful manipulation and management for the desired result to be achieved.
- Another disadvantage is that some individuals do not respond to ⁇ -blockade (Bristow, 2000, Circulation, Vol 101, 558-569). The disadvantages of known treatments and increasing incidence of heart disease as the age of the population increases means that more treatments are required.
- the present invention addresses this need and is based on the surprising discovery that 5-HT 4 receptors mediate an inotropic response in rat papillary heart muscles from failing hearts, a response which is not observed in normal rat papillary heart muscles.
- an inotropic response to serotonin (5-HT) appears to be induced in the ventricles of failing hearts.
- This surprising observation suggests that this inotropic response may be a further maladaptive compensatory mechanism in the failing heart.
- a new therapy is proposed, namely to reduce or prevent this inotropic response to 5-HT (5-hydroxytryptamine; serotonin) by blocking the 5-HT 4 receptors e.g. by the use of 5-HT 4 receptor antagonists.
- a potential new treatment for heart failure lies in the use of 5-HT 4 receptor antagonists.
- 5-HT is known to affect the CNS, the heart and the gastrointestinal tract. Effects on the heart include positive inotropic, chronotropic and lusitropic effects, all of which have been detected to date only on human atrial tissue and not ventricular tissue. In the human atrium these effects are mediated via the 5-HT 4 receptors.
- Activation of the 5-HT 4 receptor which is a 7 transmembrane G-protein coupled receptor causes the stimulation of adenylyl cyclase activity, activation of cAMP dependent protein kinase and the phosphorylation of proteins involved in excitation-contraction coupling.
- the 5-HT 4 class of receptors is one of 7 known classes of 5-HT receptors (5-HT 1-7 ). All but one of the identified receptors are 7 transmembrane-spanning G-protein coupled receptors. Several of these classes contain more than one member, encoded either by separate genes or by splice variants.
- the 5-HT 4 receptor has at least eight splice variants (5-HT 4(a) -5-HT 4(h) ). Preliminary studies have suggested that differential expression of these splice variants may occur in different tissues although it has also been shown that certain splice variants may be coexpressed in some tissues. The precise role of the different splice variants is not yet clear.
- 5-HT 4 receptor antagonists (such as that disclosed by WO 93/02677) have been proposed for use in the treatment of atrial arrhythmias and stroke, in addition to irritable bowel syndrome, gastro-oesophageal reflux disease, anxiety and/or migraine (WO 91/16045, Kaumann 1994 TiPS Vol 15, 451-455).
- this inotropic effect is mediated through 5-HT 4 receptors.
- 5-HT 4 receptors are functional in failing rat heart muscle, and not in normal rat heart muscle indicates that this induction and signalling may be a novel compensatory mechanism in heart failure.
- compensatory mechanism it is meant that the heart adapts to its reduced ability to function, in an attempt to compensate for decreased pumping.
- the adaptation as in this case, and in the case of the ⁇ -adrenergic system, may take the form of an adaptation, or induced changes in signalling mechanisms and pathways.
- blocking this compensatory mechanism for example, by using an antagonist of 5-HT 4 receptors, presents a novel and hitherto unforeseen treatment modality in combatting heart failure.
- 5-HT 4(b) mRNA levels are increased in left ventricle and in papillary muscle in rats with CHF.
- the present invention provides the use of 5-HT 4 receptor antagonists in the manufacture of a medicament for combatting heart failure.
- Also provided is a method of combatting heart failure in a mammal comprising administering a 5-HT 4 receptor antagonist to said mammal. Particularly, an effective amount of said antagonist is administered.
- the invention also provides a 5-HT 4 receptor antagonist, or a pharmaceutical composition containing such an antagonist for use in combatting heart failure.
- induction may refer to any mechanism whereby the activity of the 5-HT 4 receptor signalling pathway is increased when compared to the activity in a normal (e.g. non-failing) heart.
- the “induction” includes any mechanism whereby the 5-HT 4 receptor mediated inotropic response is induced or increased.
- An “increase” is preferably or conveniently a statistically significant increase, for example in a test for 5-HT 4 receptor mediated response as described in Example 1, or in any other test for inotropic response known in the art or described in the literature.
- heart failure includes any condition characterised by impaired cardiac function either due to reduced pump action (systolic dysfunction) or reduced filling (diastolic dysfunction). More particularly, heart failure implies impaired function of the myocardium of the heart. Particularly, chronic forms of heart failure (i.e. chronic heart failure) in general are concerned. Alternatively viewed, a subset of heart failure of particular interest is congestive heart failure (CHF), and especially chronic congestive heart failure (cCHF). However other forms of heart failure are encompassed by the invention. The invention does not however include other heart diseases or conditions which do not come under the general definition of heart failure, as above, such as atrial arrythmias which are excluded from the scope of this invention.
- CHF congestive heart failure
- cCHF chronic congestive heart failure
- heart failure can be defined as a disorder which may result from any condition that reduces the ability of the heart to pump blood.
- the cause is decreased contractility of the myocardium resulting from diminished coronary blood flow (e.g. heart failure caused by coronary artery disease (CAD) or coronary ischemic disease), but failure to pump adequate quantities of blood can also be caused by damage to heart valves, external pressure around the heart, primary cardiac muscle diseases (e.g. idiopathic dilated cardiomyopathy) or any other abnormality which makes the heart a hypoeffective pump.
- CAD coronary artery disease
- ischemic disease coronary ischemic disease
- chronic heart failure is particularly concerned.
- ischaemic heart disease ischaemic cardiomyopathy
- chronic ischaemic heart disease chronic non-ischaemic cardiomyopathy including idiopathic dilated cardiomyopathy and cardiomyopathy due to hypertension.
- Cardiac failure may be manifest in either of two ways: (1) by a decrease in cardiac output or (2) by a damming of blood in the veins behind the left or right heart.
- the heart can fail as a whole unit or either the left side or the right side can fail independently of the other. Either way this type of heart failure leads to circulatory congestion and, as a result is referred to as congestive heart failure (CHF).
- CHF congestive heart failure
- Congestive heart failure can be divided into two phases, acute (short term and unstable) CHF and chronic (long term and relatively stable) CHF.
- the division between the two is difficult to define precisely, but generally acute CHF is the stage of failure which occurs immediately after heart damage (i.e. has a rapid onset and short course) and is associated with instability in cardiac function and circulation, for example a sudden drop in cardiac output.
- Providing the acute phase is not so severe as to result in death, the sympathetic reflexes of the body are immediately activated and can compensate for the sudden loss in cardiac function. Such compensation can often be so effective and rapid that it is possible that no noticeable effect on the patient will be felt if a patient remains calm.
- systolic dysfunction For example such patients display a reduced left ventricular ejection fraction (LVEF) when compared to a “normal” person who has not suffered from heart failure. In normal persons left ventricular ejection fraction is usually above 60%, while an ejection fraction less than 40% is characterized as systolic dysfunction. Thus, a LVEF of less than 40% is characteristic of reduced heart function in patients with chronic CHF. Less common than systolic dysfunction is diastolic dysfunction in which the ejection fraction is relatively preserved (left ventricular EF>40%) or normal, but where left ventricular filling is reduced.
- LVEF left ventricular ejection fraction
- reduced cardiac function such as for example a reduced right ventricular ejection fraction, reduced exercise capacity and impaired haemodynamic variables such as a decreased cardiac output, increased pulmonary arterial pressure and increased heart rate and low blood pressure are also often observed in patients with cCHF.
- NYHA New York Heart Association
- NYHA class I Patient with cardiac disease but without resulting limitations of physical activity
- Class II Patient with cardiac disease resulting in slight limitation of physical activity
- Class III Patient with cardiac disease resulting in marked limitation of physical performance. They are comfortable at rest.
- Class IV Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present at rest.
- the invention may be used for the treatment of all classes of heart failure but particularly the classes II-IV.
- heart failure in general may be chronic or acute.
- the acute phase of heart failure for example CHF
- CHF chronic phase of heart failure
- the stability associated with the chronic phase of heart failure can take a matter of months to develop.
- a patient exhibiting symptoms of heart failure for greater than 3 months or more preferably greater than 6 months can be regarded as having chronic stable heart failure, providing that no further symptoms of acute (e.g. congestive) heart failure such as angina or evidence of myocardial infarction have occurred during this 3 month or 6 month period.
- the chronic heart failure to be treated according to the present invention may result from any cause, e.g. may be the result of a primary disease or may be secondary to another disease.
- the chronic heart failure to be treated is secondary to either idiopathic dilated cardiomyopathy (IDCM) and/or coronary ischemic disease (coronary artery disease—CAD).
- IDCM idiopathic dilated cardiomyopathy
- CAD coronary ischemic disease
- the heart failure to be treated according to the invention is post-infarction heart failure.
- the rat model used in Example 1, 2, 4 and 7 is a model of post-infarction heart failure caused by coronary artery ligation, which is a well characterised model of heart failure.
- heart failure induced by a constantly increased after load such as hypertensive heart failure.
- a rat model for this is also available, wherein heart failure is induced by aortic banding. This model has also been used to show that the 5-HT 4 receptor mediated effect is not specific to post infarction heart failure (see Example 5).
- 5-HT 4 receptor antagonist includes any agent, i.e. any compound, substance, molecule or composition (or any other agent) which may reduce or prevent any response, for example an inotropic response, to 5-HT in heart failure (i.e. the response (e.g. inotropic response) of the heart, or preferably of the myocardium).
- the antagonist may be viewed as any agent capable of inhibiting the inotropic response to 5-HT, or any other physiological or biological response to 5-HT.
- This activity may readily be assessed using any appropriate response test, for example any inotropic response test, available in the art, for example as detailed in Example 1.
- an inhibition may be observed as a decrease (e.g. a statistically significant decrease) in the response in question (e.g. inotropic response) in the presence of the agent as compared with the response (e.g. inotropic response) in the absence of the agent (i.e. antagonist).
- Any agent known in the art and/or reported in the literature as an antagonist of 5-HT 4 receptors may be used (including inverse agonists and partial agonists etc. which may function as antagonists under particular conditions, e.g. dosages/concentrations etc.).
- the term “5-HT 4 receptor antagonist” as used herein includes any compound, molecule, substance, agent or composition which attenuates the effect of 5-HT on the 5-HT 4 receptor. Such antagonism may be competitive or non-competitive.
- Competitive antagonists bind to the receptor at a region that overlaps with the agonist binding site, thereby preventing the binding of the agonist.
- the negative log of the molar concentration which at equilibrium would occupy 50% of receptors in the absence of ligand (pK B ) is the measure of potency of a competitive antagonist.
- Non-competitive antagonists bind to a site on the receptors other than the site of agonist binding and prevent agonist binding and/or receptor activation via an allosteric mechanism.
- antagonists may be reversible or irreversible. Antagonists may readily be identified by their activity at the 5-HT 4 receptor using any suitable assay or test system, conveniently any in vitro system using cells expressing stably or transiently transfected recombinant 5-HT 4 receptors or endogenous 5-HT 4 receptors, such as those described by Bach et al., (2001, supra).
- receptor antagonists are small organic compounds and these represent a preferred class of 5-HT 4 receptor antagonists for use according to the present invention.
- other “compounds” or “agents” may also be used; so long as they meet the functional criterion of inhibiting an inotropic (or any other) response to 5-HT (e.g. by blocking or inhibiting a 5-HT 4 receptor) their chemical or physical nature is unimportant.
- protein or peptide molecules may be used, which may be natural or synthetic, or derivatives or modifications of natural molecules.
- One such class of protein/peptide molecules is antibodies and their fragments or derivatives, including synthetic antibody-like molecules. Many such “binding molecules” based on antibodies are known in the art e.g.
- peptides and other molecular products of display or other (e.g. combinatorial) libraries may be used; the literature describes the synthesis and selection of many such binding molecules or binding entities by such display or other methods, and these may be used, selected to bind to the 5-HT 4 receptor.
- salts of such compounds including both organic and inorganic salts (e.g. with alkali and alkaline earth metals, ammonium, ethanolamine, diethanolamine and meglumine, chloride, hydrogen carbonate, phosphate, sulphate and acetate counterions).
- organic and inorganic salts e.g. with alkali and alkaline earth metals, ammonium, ethanolamine, diethanolamine and meglumine, chloride, hydrogen carbonate, phosphate, sulphate and acetate counterions.
- solvates with water or organic solvents such as ethanol. Such solvates are also included within the scope of this invention.
- 5-HT 4 receptor antagonists may also be prepared as pro-drugs according to principles well known in the art (e.g. as compounds which release, or which convert to, the active antagonist form when administered to the patient).
- 5-HT 4 receptor antagonists are known in the art and described in the literature (Clark, R. D. in 5-HT 4 Receptors in the Brain and Periphery, ed R. Eglen 1998 Springer Verlag and R. G. Landes Company). Any such compounds may be used according to the present invention.
- 5-HT 4 receptor antagonists may be selected from compounds comprising an aromatic ring structure with a hydrogen-bond acceptor as one substituent and a hydrogen-bond acceptor as a second substituent and a tertiary amine spaced with at least three bonds away from the aromatic ring.
- the 5-HT 4 receptor antagonists are preferably selected from compounds comprising an aromatic ring to which a carbonyl group is attached, and a basic nitrogen in the appended side chain.
- An oxygen atom is preferably adjacent to the carbonyl group.
- Suitable compounds include benzoate esters, benzoate amides, imidazolopyridines, aryl ketones, indoles, carbazimidamides, phenylcarbamates and phenylureas.
- 5-HT 4 receptor antagonists that could be used in the invention include: SB203186, 1-piperidinyl-ethyl-1H-indole-3-carboxylate (Parker S G et. al. Naunyn Schmiedebergs Arch Pharmacol. 1995 December; 353(1): 28-35); GR113808, [1-[2-methylsulphonylamino ethyl]-4-piperidinyl]methyl1-methyl-1H-indole-3-carboxylate (Kaumann A J. Br J. Pharmacol.
- DAU 6285 endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-2,3-dihydro-6-methoxy-2-oxo-1H-benzimidazole-1-carboxylate (Torres G E et. al. J Pharmacol Exp Ther. 1994 October; 271(1): 255-61); RS 39604, 1-[4-amino-5-chloro-2-(3,5-dimethoxybenzyloxy)phenyl]-3[1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]-1-propanone hydrochloride (Leung E et. al.
- SB 204070 (1-n-butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate (Leung E. et al. supra); SB 207266, N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2-a]indolelocarboxamide hydrochloride (Gaster L M et. al. J. Med Chem. 1995 Nov.
- GR125487 (1-[2-[(methyl-sulphonyl)amino] ethyl]-4-piperidinyl-methyl-5-fluoro-2-methoxy-1H-indole-3-carboxylate) (Gale et al 1994 Br. J. Pharmacol., 113, 120P); (3- ⁇ -tropanyl)-1H-indazole-3-carboxylic acid (WO91/16045); ICS205-930 (tropisetron) (Dumuis A. et al. (1998), Eur J. Pharmacology 146 187-188); R50595 (FR76530) (Meulemans A L and Schuurkes J A.
- 5-HT 4 receptor antagonists may also be used.
- 5-HT 4 receptor antagonists are further described in the following patent documents: WO91/16045, WO93/02677, WO93/18036, WO93/05040, WO 93/03725, WO 93/05038, PCT/EP93/03054, PCT/GB93/01895, PCT/EP93/02808, PCT/GB93/02028, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/GB94/00172 (all to Smith Kline Beecham plc), EP-A-501322 (Glaxo), U.S. Pat. No.
- the 5-HT 4 receptor antagonists will inhibit any 5-HT 4 receptor mediated action of 5-HT in the failing heart.
- the antagonist may thus for example inhibit all 5-HT 4 receptor mediated actions.
- inhibition is meant that the response to 5-HT, for example the inotropic response, when compared to an untreated individual, is reduced.
- This reduction includes any measurable decrease in a response to 5-HT (e.g. the ventricular inotropic response) in an individual when compared to the 5-HT response (e.g. the ventricular inotropic response) in an individual taken at an earlier time, before treatment.
- the measurable decrease will preferably be statistically significant. More preferably the measurable decrease will be such that the 5-HT response (e.g.
- the ventricular inotropic response is substantially inhibited by the 5-HT 4 receptor antagonist. Most preferably the response is blocked. By blocked it is meant that no measurable response (e.g. the inotropic response) to 5-HT is detected in the presence of the 5-HT receptor antagonist.
- the decrease will be associated with the improved cardiac performance of the patient.
- Cardiac performance may be assessed according to methods and practices well known in the art.
- treatment in accordance with the present invention includes an improvement or alleviation of any of the symptoms associated with the heart failure and also an improved quality of life for a patient and, ultimately a prolonged lifetime and improved survival.
- Treatment in accordance with the present invention also includes an improvement or increase of the functionality of the heart or, in other words an improvement or increase in cardiac function or performance.
- treatment in accordance with the present invention may result in an improvement or increase in any one or more of the symptoms and functional parameters associated with heart failure patients and in particular the following symptoms and parameters of the patient.
- the first symptom and parameter associated with improved cardiac function in heart failure patients is an increase in ventricular ejection fraction and in particular left ventricular ejection fraction (LVEF).
- LVEF left ventricular ejection fraction
- This can be assessed by standard methods well known and documented in the art, for example by echocardiography, ECG synchronized gated radionuclide ventriculography (MUGA scan), angiography or magnetic resonance (MR) imaging, and is normally carried out when the subject is at rest.
- An improvement in LVEF has been found to be associated with improved survival amongst CHF patients (Cintron et al., 1993, Circulation Vol 87, Supplement VI, 17-23). Thus, this is an important and advantageous parameter to be improved in subjects treated in accordance with the present invention. RVEF may also be increased.
- LVEF LVEF
- a number of other parameters associated with cardiac performance may be improved in accordance with the present invention.
- One of these is a significant improvement in overall clinical status and thus clinical performance as evaluated by NYHA functional class.
- the NYHA functional class of a patient may be reduced after treatment with 5-HT 4 antagonists in accordance with the present invention.
- Such a clinical evaluation may normally be carried out by a trained cardiologist.
- exercise capacity of the patients is measured by peak oxygen uptake and peak work load.
- a decreased exercise capacity is an inconvenient and potentially dehabilitating symptom of many heart failure patients.
- Methods for measuring exercise capacity are well known and documented in the art. For example exercise testing can be carried out using an electrically braked bicycle ergometer. An exemplary protocol might consist of a starting work rate of 20 W increasing by 20 W every second minute until exhaustion (defined as an inability to keep the pedalling rate steady at 60 rpm).
- Oxygen uptake (VO 2 ) can be measured using for example the EOS/SPRINT system. Peak VO 2 , is taken as the highest VO 2 observed.
- hemodynamic status and echocardiographic variables may also be observed. These are again indicative of improved cardiac function. For example a significant decrease in pulmonary capillary wedged pressure and in pulmonary artery pressure may be observed, together with an increase in peak heart rate, peak systolic blood pressure and mitral velocity deceleration time. Echocardiographic variables may conveniently be measured by echocardiography carried out by a trained cardiologist and haemodynamic variables can conveniently be assessed by right-sided heart catheterization according to standard techniques.
- Nt-proANP Another important variable which may be assessed is the plasma level of Nt-proANP.
- An increased or generally high level of Nt-proANP has been recognised as a marker of cardiac dysfunction.
- levels of Nt-proANP have been shown in the past to correlate with pulmonary artery pressures in CHF and provide important prognostic information in CHF patients (Gott Kunststoff et al., J. Am. Coll. Cardiol. 1989; 13: 1534-1539).
- Levels of Nt-proANP in a blood sample can be measured in a number of ways well known and documented in the art, for example by radioimmunoassay. Prior to the immunoassay, plasma is separated from a blood sample taken from the patient again by methods well known and documented in the art.
- the above described “improvement” or “increase” in the symptoms and parameters includes any measurable improvement or increase when the parameter in question is compared with the equivalent parameter in a non-treated individual or when the parameter in question is compared with the equivalent parameter in the same individual taken at an earlier time point (e.g. comparison with a “base line” level).
- the improvement or increase will be a statistically significant one.
- the improvement or increase in the symptoms and parameters will be associated with the improved health of the patient concerned and more preferably a prolonged survival.
- a parameter is generally regarded as significant if a statistical comparison using a two-tailed significance test such as a Student t-test or Mann-Whitney U Rank-Sum test shows a probability value of ⁇ 0.05.
- a further aspect of the present invention relates to the use of a 5-HT 4 receptor antagonist in the manufacture of a medicament for use in the improvement of cardiac function, particularly cardiac function in heart failure.
- the present invention relates to the use of a 5-HT 4 receptor antagonist in the manufacture of a medicament for use in the increase of ventricular function, particularly preferably left ventricular function (e.g. LVEF), more particularly in heart failure.
- a 5-HT 4 receptor antagonist in the manufacture of a medicament for use in the increase of ventricular function, particularly preferably left ventricular function (e.g. LVEF), more particularly in heart failure.
- LVEF left ventricular function
- a yet further aspect of the present invention relates to the use of a 5-HT 4 receptor antagonist in the manufacture of a medicament for use in the reduction of plasma Nt-proANP levels.
- a reduction in the plasma levels of Nt-proANP is an indicator of improved cardiac function and performance.
- “Reduction” as used herein includes any measurable reduction when the parameter in question is compared with the equivalent parameter in a non-treated individual or when the parameter in question is compared with the equivalent parameter in the same individual taken at an earlier time point (e.g. comparison with a “base line” level).
- the reduction is statistically significant as discussed above.
- the reduction in the levels of Nt-proANP will be associated with an improved feeling of health in the patient concerned and more preferably a prolonged survival.
- the invention provides a method of improving cardiac function in a mammal (for example a mammal with heart failure) which method comprises administering to said mammal a pharmaceutically effective amount of a 5-HT 4 receptor antagonist.
- Any mammal may be treated, for example humans and any livestock or domestic animal, e.g. mice, rats, pigs, cats, dogs, sheep, rabbits, horses, cows or monkeys. However preferably the mammals are humans.
- the 5-HT 4 receptor antagonist is conveniently formulated in a pharmaceutical composition for use according to the present invention.
- the present invention also provides a pharmaceutical composition for use in combatting heart failure, said composition comprising a 5-HT 4 receptor antagonist together with at least one pharmaceutically acceptable carrier diluent or excipient.
- the active ingredient in such compositions may comprise from 0.05% to 99% by weight of the formulation, for example from 0.1% to 1.0% or around 0.5%.
- concentration of active ingredient in the formulation will depend on the type of formulation. For example, enteral products (e.g. tablets and capsules) can typically have 5% to 50% active ingredients by weight, whereas parenteral formulations usually have a lower concentration of active compound e.g. 0.1% to 3% active ingredient by weight, for example in an injection solution.
- pharmaceutically acceptable is meant that the ingredients must be compatible with other ingredients of the composition as well as physiologically acceptable to the recipient.
- compositions may be formulated according to any of the conventional methods known in the art and widely described in the literature.
- the active ingredient i.e. 5-HT 4 receptor antagonist
- the active ingredient may be incorporated, optionally together with other active substances, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations which are suitable or can be made suitable for subcutaneous, intramuscular, intravenous or any other administration such as powders, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, ointments, sterile injectable solutions, sterile packaged powders, and the like.
- the pharmaceutical composition comprising the 5-HT 4 receptor antagonist may be prepared in a form appropriate for infusion or injection into a patient.
- Such infusion or injection is preferably intravenous (i.v.) but may also be given subcutaneously (s.c.) or intramuscularly (i.m.).
- compositions may be provided in a form adapted for oral or parenteral administration.
- Alternative pharmaceutical forms thus include plain or coated tablets, capsules, suspensions and solutions containing the active component optionally together with one or more inert conventional carriers and/or diluents.
- Suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, maltose, glucose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable mixtures thereof.
- compositions may additionally include lubricating agents, wetting agents, emulsifying agents, suspending agents, preserving agents, sweetening agents, flavouring agents, and the like.
- the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- Solubilizing and/or stabilizing agents may also be used, e.g. cyclodextrins (CD) ⁇ , ⁇ , ⁇ and HP- ⁇ cyclodextrin.
- CD cyclodextrins
- Suitable doses will vary from patient to patient and can be determined by the physician in accordance with the weight, age and sex of the patient, mode of administration, and the severity of the condition and also the particular antagonist used for treatment.
- Exemplary unit doses for oral administration contain 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 50 mg), of the active ingredient.
- the daily dose for oral administration is normally in the range of approximately 0.01 to 10 mg/kg/day, more usually 0.1 to 5 mg/kg/day, for example 0.1 to 2 mg/kg/day.
- a 70 kg adult would receive a daily dose of 1 to 700 mg or 0.7 to 700 mg, more usually 1 to 350 mg or 7 to 350 mg for example 7 to 140 mg.
- the doses can be between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, the compound being administered 1 to 4 times a day.
- the improvements seen in patients treated in accordance with the present invention may be immediate (e.g. after a few days), or may be seen after a few weeks or a few months depending on the individual patient. Once the initial improvement is seen, continued improvement over the subsequent weeks and months may also occur. As indicated above, treatment can be continued for as long as is desired or is necessary.
- a 5-HT 4 receptor antagonist in accordance with the present invention may be in place of, or preferably in addition to (i.e. in combination with) the use of other drugs for treatment of heart failure.
- other drugs known to treat heart failure might be included in the pharmaceutical compositions described above or may be administered separately, in a manner appropriate for the drug concerned.
- the present invention provides a product comprising (a) a 5-HT 4 receptor antagonist and (b) a second drug (e.g. a second agent effective for the treatment of heart failure) as a combined preparation for simultaneous, separate or sequential use in the treatment of heart failure or in improving cardiac function.
- a product comprising (a) a 5-HT 4 receptor antagonist and (b) a second drug (e.g. a second agent effective for the treatment of heart failure) as a combined preparation for simultaneous, separate or sequential use in the treatment of heart failure or in improving cardiac function.
- Suitable 5-HT 4 receptor antagonists are defined above.
- Suitable second drugs or agents are well known and documented in the art and include known drugs for use in the treatment of heart disorders, for example diuretics, vasodilators, inotropic drugs such as digoxin, or other compounds such as anticoagulants, ⁇ blockers, angiotensin II blockers, angiotensin converting enzyme inhibitors or aldosterone antagonists may be used as discussed above.
- a particularly advantageous combination of 5-HT 4 receptor antagonist is with ⁇ -blockers.
- FIG. 1 shows the inotropic effect of serotonin in heart failure rats.
- Original paper recording in a papillary muscle from a representative Chronic heart failure rat.
- Serotonin (10 ⁇ mol/l) induced a positive inotropic response in the presence of atropine, timolol and prazosin.
- Inset Development of the inotropic response, expressed as F max in percent of individual maximal response, in Chronic heart failure papillary muscles following addition of serotonin to 10 ⁇ mol/l.
- Horizontal error bar represents time ⁇ SEM to 50% relative response. The time needed to reach each percentile is the mean value from 10 papillary muscles.
- FIG. 2 shows the inotropic response to serotonin (10 ⁇ mol/l) and isoprenaline (100 ⁇ mol/l) in papillary muscles from Chronic heart failure and sham-operated rats.
- a) Increase in development of force expressed as percent above control.
- b) Representative examples of single recordings of contraction-relaxation cycles in a papillary muscle exposed to serotonin and isoprenaline.
- the figure shows representative contractions before addition of agonist (_), at maximal steady state inotropic response to 10 ⁇ mol/l serotonin ( - - - - ) and at maximal steady state inotropic response to 100 ⁇ mol/l isoprenaline ( . . . . ).
- Ordinate Development of tension in arbitrary units. Abscissa: Time after initiating stimulus.
- FIG. 3 shows the reversal of the inotropic response to serotonin by cholinergic stimulation.
- the figure shows the increase in contractile force expressed as percent above control in papillary muscles from Chronic heart failure rats in response to cumulative addition of 10 ⁇ mol/l serotonin (5-HT), 30 ⁇ mol/l carbachol (CCh) and 1 ⁇ mol/l atropine (Atropine). Note that carbachol reversed and atropine restored the inotropic response to serotonin.
- FIG. 4 shows the reversal of the inotropic response to serotonin by the 5-HT 4 -selective antagonist GR113808.
- the figure shows representative contraction-relaxation cycles in a papillary muscle from a Chronic heart failure rat before addition of agonist (_), at maximal steady state inotropic response to 10 ⁇ mol/l serotonin ( . . . . ) and following reversal by 1 ⁇ mol/l GR113808 ( - - - - ).
- Ordinate Development of tension in arbitrary units. Abscissa: Time after initiating stimulus.
- FIG. 5 shows that the lack of ketanserin effect eliminates involvement of 5-HT 2A -receptors.
- FIG. 6 shows that the high affinity of GR 113808 confirms involvement of 5-HT 4 -receptors.
- FIG. 7 shows expression of 5-HT 4(b) , 5-HT 2A and ANP mRNA in left ventricle and papillary muscle of sham treated and CHF rats.
- Messenger RNA for 5-HT 4(b) receptor (upper panels), 5-HT 2A receptor (middle panels) and ANP (lower panels) was quantified, and normalised to GAPDH.
- FIG. 8 shows the relationship between the maximum inotropic response to 10 ⁇ M serotonin in papillary muscle and infarction size (A) and 5-HT 4 , 5-HT 2A and ANP mRNA levels in non-infarcted left ventricle tissue related to infarction size (B).
- FIG. 9 shows concentration-response curves for serotonin in papillary muscles of rats 6 weeks after myocardial infarction in the absence and presence of 5 nM SB203186 or 5 nM RS39604. Inotropic response (dF/dt) is expressed in percent of maximum for each papillary muscle.
- FIG. 10 shows representative average contraction-relaxation cycles in a papillary muscle from the heart of a rat with CHF 6 weeks after aortic banding before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- FIG. 11 shows representative average contraction-relaxation cycles in a trabecular muscle from an explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- FIG. 12 shows representative average contraction-relaxation cycles in a trabecular muscle from an explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- FIG. 13 shows maximal inotropic response to ⁇ adrenoceptor stimulation in rats with CHF treated for six weeks with SB207266 or placebo.
- mice Male, Wistar rats (M ⁇ llegaard Breeding and Research Centre, Skensved, Denmark), weighing about 320 g were intubated and ventilated with 68% N 2 O, 29% O 2 and 2-3% Isofluran (Abbot Laboratories, USA). An extensive myocardial infarction (MI) was induced by a proximal ligation of the left coronary artery. Six weeks later the rats were anaesthetized and ventilated on the respirator with 2.2% Isofluran. Left ventricular pressures were measured (Sjaastad et al., 2000, J. Appl.
- MI myocardial infarction
- LVEDP left ventricular end diastolic pressure
- the infarct comprised most of the left ventricular free wall and also extended to the apex and the base of the papillary muscle. Echocardiography has previously demonstrated severely depressed myocardial function (Sjaastad et al. 200, supra).
- the sham-operated animals (SHAM) were subjected to the same surgical procedure but the coronary artery was not ligated.
- the muscles were transported to a separate laboratory and mounted in organ baths.
- a relaxing solution with a Ca ++ /Mg ++ concentration ratio of 1:8 comparable to that of St. Thomas' Hospital cardioplegic solution.
- the papillary muscles were mounted in organ baths containing the relaxing solution and allowed to adapt at 31° C.
- the muscles were field stimulated with alternating polarity at 1 Hz with impulses of 5 msec duration and current about 20% above individual threshold (10-15 mA, determined in each experiment).
- the isometrically contracting muscles were stretched to the maximum of their length-tension curve.
- the force was recorded and analysed as previously described (Skomedal et al., 1997, J. Pharmacol. Exp. Ther. 280: 721-729).
- the muscles were allowed to equilibrate for 90 minutes.
- prazosin ⁇ 1 -AR antagonist
- timolol ketanserin
- GR113808 5-HT 4 -selective antagonist
- CRC Averaged contraction-relaxation cycles
- Agonist was added cumulatively or as a single bolus directly to the organ baths and was completely mixed in the solution within 2-3 seconds.
- the concentration-dependent inotropic and lusitropic responses to 5-HT 4 -receptor stimulation by serotonin were obtained in the presence of prazosin (1 ⁇ mol/l) and timolol (3 ⁇ mol/l or 1 ⁇ mol/l) atropine (1 ⁇ mol/l) and ascorbate (10 ⁇ mol/l), respectively.
- Concentration-response curves for serotonin were obtained by adding serotonin cumulatively in the absence and presence of ketanserin (0.1 ⁇ mol/l).
- Concentration-response curves for 5-HT 4 -receptor stimulation in the presence of ketanserin were performed in the absence and presence of 0.5 nmol/l GR113808 and the relative shift of the curves was used to calculate the K b for GR113808.
- serotonin was added as a single dose (10 ⁇ mol/l) the experiments were performed in the absence of ketanserin.
- the presence of either antagonist did not influence the basal or maximal function of the muscles with regard to mechanical performance or electrical stimulation threshold (data not shown).
- the different agonists were added directly to the organ baths in increasing concentrations until supramaximal concentrations of agonist were obtained with respect to maximal inotropic response.
- the responses for each concentration of agonist were generally calculated as percent of maximal response.
- the concentration-response curves constructed from papillary muscle experiment were constructed according to Ariens and Simonis (1964, supra), by estimating centiles (EC 10 to EC 100 ) for each single experiment and calculating the corresponding means. This calculation provides mean curves that express the response as fractional response or percent of maximum and display horizontal positioning and the correct mean slope of the curves.
- the inhibition constants K b were calculated from the Schild equation, based on the relative shifts of the concentration-response curves for receptor stimulation.
- Serotonin (5-hydroxytryptamine hydrochloride, 5-HT) was from Sigma (St. Louis, Mo., USA).
- GR 113808 ( ⁇ 1-[2-(methyl-sulphonylamino)ethyl]4-piperidinyl ⁇ methyl 1-methyl-1H-indole-3-carboxylate) maleate was from Tocris (Bristol, UK).
- Ketanserin (3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione) tartrate was from RBI (Natick, Mass., USA).
- Prazosin hydrochloride, timolol maleate was from Sigma (St. Louis, Mo., USA).
- the inotropic responses through the respective receptors were not additive indicating coupling to the same signalling pathway.
- GR113808 is a selective 5-HT 4 -antagonist with a pKi of 9.2-9.7 (Gale et al., 1994, Br. J. Pharmacol. 111: 332-338), and 1 ⁇ mol/l GR113808 completely reversed the inotropic response evoked by 10 ⁇ mol/l serotonin ( FIG. 4 ).
- 2 a illustrates a consistently lower inotropic effect in all experiments when measured after a full concentration-response curve as opposed to a direct stimulation with a high concentration (e.g. 10 ⁇ mol/l) of serotonin. This difference may reflect desensitisation of the response during the continuous stimulation with increasing concentrations of serotonin, as is done to achieve the concentration-response curves.
- RT-PCR Quantitative Reverse Transcriptase Polymerase Chain Reaction
- Non-infarcted left ventricle tissue (30-50 mg, mainly septum), collected immediately after removal of the papillary muscle, or papillary muscle (15-30 mg including some left ventricular wall) collected after completion of functional analyses, stored in RNAlater (Ambion) until use, was flash frozen and reduced to powder under liquid nitrogen.
- Total RNA was isolated from tissue powder homogenized in 1 ml TRIZOL (Invitrogen), followed by mRNA extraction (Bach et al. 2001 supra) and oligo-dT-primed first strand cDNA synthesis (Medhurst et al. 2001 Brain Res Mol Brain Res 90: 125-134). A standard curve with 5-300 ng mRNA was made to control for reverse transcription and PCR quantification.
- Quantitative RT-PCR (Medhurst et al. supra) was done in 25 ⁇ l reactions with TaqMan Universal PCR Master Mix (Applied Biosystems) containing 5 mM Mg 2+ , 300 nM of each primer, 200 nM probe and long template cDNA. GAPDH was quantified separately for normalization with 0.1 ng cDNA template. Raw data were collected and analyzed with Sequence Detector Software (SDS version 1.7; Applied Biosystems) (Bustin et al. 2000, supra). Results are expressed as mean ⁇ SEM from n animals. P ⁇ 0.05 was considered statistically significant (nonparametric Mann-Whitney test).
- Quantitative RT-PCR was used to determine the level of mRNA encoding 5-HT 4(b) receptor, 5-HT 2A receptor, and the heart failure marker ANP normalized to the level of GAPDH mRNA.
- 5-HT 4(b) mRNA levels were four and 18-fold higher in CHF vs. Sham, whereas 5-HT 2A mRNA levels were unchanged and ANP mRNA levels increased ( FIG. 7 ).
- the ratio between normalized 5-HT 4(b) and 5-HT 2A mRNA levels was increased in CHF in both left ventricle and papillary muscle, confirming increased 5-HT 4(b) mRNA level relative to 5-HT 2A , independent of GAPDH (Table 2).
- MI nf rats In papillary muscles from MI nf rats i.e. rats in which symptoms of CHF were not obtained, despite having undergone surgery to induce myocardial infarction, serotonin (10 ⁇ M) elicited an inotropic response qualitatively similar to the response observed in CHF animals.
- the magnitude of the response correlated positively with infarction size up to 30-40% of the inner myocardial surface in MI nf animals ( FIG. 8A ).
- MI nf hearts with infarct size 30-40% the inotropic effect was of the same magnitude as in CHF hearts which all had infarct size >40%.
- the figure shows concentration-response curves for serotonin in papillary muscles of rats 6 weeks after myocardial infarction in the absence and presence of 5 nM SB203186 or 5 nM RS39604.
- Inotropic response (dF/dt) is expressed in percent of maximum for each papillary muscle.
- the pEC 50 value for serotonin in the absence of blocker was 7.25 ⁇ 0.2.
- the pEC 50 value for serotonin in the presence of 5 nM SB203186 was 6.39, corresponding to a pK b value of 9.1.
- the pEC 50 value for serotonin in the presence of 5 nM RS39604 was 6.26, corresponding to a pK b value of 9.2. This is consistent with the inotropic response to serotonin being mediated via 5-HT 4 receptors.
- a second model of heart failure was then used to study the 5-HT 4 receptor-mediated inotropic effect of serotonin; namely a model of rat hypertensive heart failure.
- This study uses a rat model of heart failure obtained by aortic banding. In this model, the heart failure is induced by a constantly increased afterload, somewhat reminiscent of human hypertensive heart failure. This study was performed to clarify whether it is the heart failure as such, or the cardiac infarction preceding the heart failure that underlies the induction of 5-HT 4 receptors in the post-infarction model.
- Trans-aortic constriction (aortic banding) of the ascending aorta was induced in 200 g male Wistar rats under anaesthesia, induced by 63% N 2 O, 32% O 2 and 5% Isoflurane and maintained by 66% N 2 O, 33% O 2 and 1-2% Isoflurane.
- a right-sided thoracotomi was performed through a 3-4 cm long cutaneous incision, the pericardium was opened and the ascending aorta identified and dissected free of surrounding tissue.
- a ligature was knit around the ascending aorta and a metal probe with diameter 0.9 mm. The metal probe was then removed.
- the result was a constriction of the ascending aorta with internal diameter about 0.9 mm.
- the thorax was then closed with 3-0 silk sutures and the skin closed with Dexon 1 sutures.
- the animals received post-operative analgesia with buprenorphine 0.09 mg subcutaneously and were allowed to wake up in a 30° C. environment. After six weeks the animals were again placed under anaesthesia as during the primary surgery, and an echocardiographic examination was performed. Finally the thorax was opened and the heart was removed for preparation of posterior left ventricular papillary muscles as described (Sjaastad et al. 2003 Acta physiol Scand 177: 449-458). The rat was considered to have CHF.
- the experiment was performed in the presence of blockers (added 90 min prior to serotonin) of adrenergic and muscarinic cholinergic receptors (prazosin 1 ⁇ M, timolol 1 ⁇ M, atropine 1 ⁇ M).
- FIG. 10 shows representative average contraction-relaxation cycles in a papillary muscle from the heart of a rat with CHF 6 weeks after aortic banding before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- Serotonin (10 ⁇ M) elicited a positive inotropic response comparable in magnitude and characteristics to the positive inotropic response to 100 ⁇ M isoproterenol (enough to surmount the blockade by 1 ⁇ M timolol).
- the positive inotropic response to serotonin was reversed by 1 ⁇ M of the 5-HT 4 antagonist GR113808, indicating that the response is mediated through 5-HT 4 receptors.
- FIG. 11 shows representative average contraction-relaxation cycles in a trabecular muscle from the explanted post infarct human heart before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- the heart was explanted from a patient who had survived a small myocardial infarction and died in hospital from subarachnoidal haemorrhage.
- the experiment was performed in the presence of blockers (added 90 min prior to serotonin) of adrenergic and muscarinic cholinergic receptors (prazosin 1 ⁇ M, timolol 1 ⁇ M, atropine 1 ⁇ M).
- serotonin (10 ⁇ M) elicited a positive inotropic response amounting to about 10% of the positive inotropic response to 100 ⁇ M isoproterenol (enough to surmount the blockade by 1 ⁇ M timolol).
- the positive inotropic response to serotonin was reversed by 1 ⁇ M of the 5-HT 4 receptor antagonist GR113808, indicating that the response is mediated through 5-HT 4 receptors.
- a heart was also explanted from a patient who had received a heart transplant due to heart failure from dilated cardiomyopathy. Trabecular muscles were prepared and the contraction-relaxation cycles (CRCs) were recorded and analysed as described above. In addition to the presence of blockers as above, the positive inotropic responses to serotonin and isoproterenol were enhanced by the presence of the phosphodiesterase inhibitor IBMX (isobutyl-methyl-xanthine; 35 ⁇ M).
- IBMX isobutyl-methyl-xanthine
- FIG. 12 shows representative average contraction-relaxation cycles in a trabecular muscle from this explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 ⁇ M serotonin, following reversal of the serotonin response with 1 ⁇ M GR113808 and at maximal steady state inotropic response to 100 ⁇ M isoproterenol.
- serotonin (10 ⁇ M) elicited a positive inotropic response amounting to about 32% of the positive inotropic response to 100 ⁇ M isoproterenol (enough to surmount the blockade by 1 ⁇ M timolol).
- the positive inotropic response to serotonin was reversed by 1 ⁇ M of the 5-HT 4 receptor antagonist GR113808, indicating that the response is mediated through 5-HT 4 receptors.
- MI myocardial infarction
- the rats received subcutaneous implantation of 2 ml Alzet miniosmotic pumps (Alza, Palo Alto, Calif.) containing solvent (100 ⁇ M ascorbic acid, 50 ⁇ M EDTA in water; placebo group) or solvent containing 50 mM of the 5-HT 4 antagonist SB207266 (treatment group).
- solvent 100 ⁇ M ascorbic acid, 50 ⁇ M EDTA in water; placebo group
- solvent containing 50 mM of the 5-HT 4 antagonist SB207266 treatment group.
- the pumps were replaced with new pumps after three weeks to obtain a total treatment time of six weeks.
- results are shown in FIG. 13 and indicate a trend towards normalisation of myocardial function, as judged by the trend towards normalisation of the CHF-induced reduction of maximal inotropic response to ⁇ -adrenoceptor stimulation, by treatment with the 5-HT 4 antagonist SB207266.
- the active ingredients are passed through a 24 mesh sieve and blended with lactose, microcrystalline cellulose and magnesium stearate. The resulting mixture is pressed into tablets. Tablet weight is 200 mg and each tablet contains 10 mg GR113808.
- the active ingredients are passed through a 24 mesh sieve and blended with lactose.
- the mixture is filled into gelatin capsules (200 mg) using suitable machinery.
- Each capsule contains 5 mg SB207266 and 50 mg atenolol.
- SB207266 (as hydrochloride salt) and sodium chloride are dissolved in water for injection to form an isotonic solution.
- the mixture is filled into vials (10 ml) with rubber stoppers and sterilised by heating in an autoclave for 20 minutes at 121 degrees centrigade.
- Each vial contains 10 ml and 1 mg SB207266 per ml.
- the active ingredients are passed through a 24 mesh sieve and blended with lactose.
- the mixture is filled into gelatin capsules (200 mg) using suitable machinery.
- Each capsule contains 5 mg SB207266 and 50 mg metoprolol tartrate.
- the active ingredients are passed through a 24 mesh sieve and blended with lactose.
- the mixture is filled into gelatin capsules (200 mg) using suitable machinery.
- Each capsule contains 5 mg SB207266 and 10 mg enalapril maleate.
- the active ingredients are passed through a 24 mesh sieve and blended with lactose.
- the mixture are filled into gelatin capsules (200 mg) using suitable machinery.
- Each capsule contains 5 mg SB207266 and 50 mg losartan potassium salt.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure (5HT- 4 Receptor Antagonist Plus ⁇ / ⁇ -Blocker) SB207266(as hydrochloride salt) 5.5 g carvedilol 12.5 g lactose 182 g
- the active ingredients are passed through a 24 mesh sieve and blended with lactose.
- the mixture is filled into gelatin capsules (200 mg) using suitable machinery.
- Each capsule contains 5 mg SB207266 and 12.5 mg carvedilol.
- GR113808 salt is milled down to a particle size of approximately 20 microns.
- a suspension of the salt is prepared in molten glyceride of fatty acid and filled into suppository moulds.
- the weight of each suppository is 200 mg with unit dose of 15 mg GR113808.
Abstract
Description
- The present invention relates to heart failure and in particular the use of 5-HT4 receptor antagonists for the treatment of heart failure and the symptoms associated therewith.
- Heart failure is a disease that primarily affects the elderly and with a population which is ageing progressively it is likely that the prevalence of this disease will continue to increase. New and improved methods of treating heart failure are therefore required.
- Heart disorders or diseases, which are generally characterised by impaired cardiac function, e.g. heart failure, affect a large number of people worldwide and in particular in the Western world. Heart disorders or diseases are responsible for a reduced quality of life and premature death in a significant proportion of sufferers. Heart disorders occur in men, women, and children of both sexes, but are particularly prevalent in men and in elderly or middle aged people.
- Heart failure is characterized by impaired cardiac function either due to reduced pump function (systolic dysfunction) or reduced filling (diastolic dysfunction). There are a number of different causes of heart failure of which the most common in the western world is coronary artery disease. Other common causes are cardiomyopathy (primary or secondary), hypertension, valvular diseases, and congenital defects.
- Approximately 70% of heart failure in the western world is caused by coronary artery disease, which is usually due to atherosclerosis. Atherosclerosis will result in narrowing of the vessels in the heart leading to inadequate blood supply to the myocardium (muscle cells). Such heart disorders which involve a reduced supply of blood to the heart are sometimes given the general term “ischemic heart disease”. Ischemic heart disease (or ischemic cardiomyopathy) is the major etiologic group of heart failure in the Western world.
- A reduced blood supply to the heart can manifest itself as angina pectoris (pain in the chest), acute myocardial infarction (which is the result of acute coronary artery occlusion causing a damaged myocardium with scar tissue; such an area cannot sustain cardiac muscle function), and sudden deaths. If the blood supply to the heart is reduced over periods of weeks to years, or if the myocardium has been substantially weakened by infarction with scar tissue, the heart function will become weakened with reduced pumping ability leading to the clinical manifestation of chronic heart failure.
- Congestive heart failure (CHF, of which chronic congestive heart failure (cCHF) is a subset), is characterised by impaired left ventricular function, increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and dyspnea. Circulatory congestion results from the decrease in cardiac output or from the damming of blood in the veins behind the left or right heart.
- The more common forms of heart failure that result from damage to the heart often cannot be cured, but treatment may improve symptoms.
- Current treatment for heart failure is based partially on preventative measures such as controlling diet, for example reducing or excluding caffeine and sodium, weight loss and exercise. Surgical means are used in more serious cases, for example coronary bypass surgery which eases symptoms by increasing bloodflow to the heart, coronary angioplasty or transplantation, if the heart has lost significant pumping capacity.
- Drug treatments are also used. For example angiotensin converting enzyme (ACE) inhibitors slow the progression of heart failure by inhibiting the formation of angiotensin and causing vasodilation. The use of other diuretics is also common, which relieve water retention in the body thus easing the workload on the heart. Digitalis preparations such as digoxin are also used to increase the force of the heart's contractions.
- Betablockers are another commonly used treatment for heart failure, alone or in combination with ACE inhibitors. The failing heart is adrenergically activated, in contrast to the normally functioning human ventricle when in a resting state (Bristow, 2000, Circulation, Vol 101, 558-569). The increase in cardiac adrenergic drive appears to be damaging to the failing heart and is thus termed a maladaptive response. This response appears to be associated with changes in the composition of the adrenoceptors during heart failure with up-regulation of α1 adrenoceptors and the down-regulation of β adrenoceptors. In addition, mouse models overexpressing activated adrenoceptors show cardiomyopathy and systolic dysfunction. Chronic adrenergic signalling is therefore considered to be a harmful compensatory mechanism in the failing human heart.
- In the end stage failing heart, 50-60% of the total signal transducing potential is lost. Blockade of the remaining signalling capacity using betablockers complements the heart's endogenous antiadrenergic strategy of desensitisation, which is considered to be an adaptive change (Bristow, 2000, Circulation, Vol 101, 558-569).
- By inhibiting the remaining signalling potential of β adrenergic receptors using β blockers, a relatively effective method of treating heart failure has been developed and used with some success.
- Nonetheless, whilst β blockers have been used with relative success, there is a continuing need for further drugs and treatments for heart disease. β blocker treatment is not successful for all patients as some patients show contraindications to β blockade such as reactive airways disease, sinus node or conduction system disease with bradycardia. Furthermore the target doses require careful manipulation and management for the desired result to be achieved. Another disadvantage is that some individuals do not respond to β-blockade (Bristow, 2000, Circulation, Vol 101, 558-569). The disadvantages of known treatments and increasing incidence of heart disease as the age of the population increases means that more treatments are required.
- The present invention addresses this need and is based on the surprising discovery that 5-HT4 receptors mediate an inotropic response in rat papillary heart muscles from failing hearts, a response which is not observed in normal rat papillary heart muscles. Thus, an inotropic response to serotonin (5-HT) appears to be induced in the ventricles of failing hearts. This surprising observation suggests that this inotropic response may be a further maladaptive compensatory mechanism in the failing heart. Based on this, a new therapy is proposed, namely to reduce or prevent this inotropic response to 5-HT (5-hydroxytryptamine; serotonin) by blocking the 5-HT4 receptors e.g. by the use of 5-HT4 receptor antagonists. Thus, we propose that a potential new treatment for heart failure lies in the use of 5-HT4 receptor antagonists.
- 5-HT is known to affect the CNS, the heart and the gastrointestinal tract. Effects on the heart include positive inotropic, chronotropic and lusitropic effects, all of which have been detected to date only on human atrial tissue and not ventricular tissue. In the human atrium these effects are mediated via the 5-HT4 receptors. Activation of the 5-HT4 receptor, which is a 7 transmembrane G-protein coupled receptor causes the stimulation of adenylyl cyclase activity, activation of cAMP dependent protein kinase and the phosphorylation of proteins involved in excitation-contraction coupling.
- The 5-HT4 class of receptors is one of 7 known classes of 5-HT receptors (5-HT1-7). All but one of the identified receptors are 7 transmembrane-spanning G-protein coupled receptors. Several of these classes contain more than one member, encoded either by separate genes or by splice variants. The 5-HT4 receptor has at least eight splice variants (5-HT4(a)-5-HT4(h)). Preliminary studies have suggested that differential expression of these splice variants may occur in different tissues although it has also been shown that certain splice variants may be coexpressed in some tissues. The precise role of the different splice variants is not yet clear.
- Previous studies have identified 5-HT responses in human and porcine atrial tissue, occurring via the 5-HT4 receptor, including increased heart rate, contractile force and hastening of relaxation. These studies failed to show any effect of 5-HT on human (Jahnel et al., 1992, Naunyn Schmiedeberg's Arch Pharmacol, Vol 346:482-485; Schoemaker et al European Journal of Pharmacology 1993 Vol 230, 103-105) and porcine (Schoemaker et al., 1992, Naunyn Schmiedeberg's Arch. Pharmacol, 346: 486-489; Lorrain et al. 1992, Eur J Pharmacol 229: 105-108; Saxena, 1992, Naunyn Schmiedeberg's Arch. Pharmacol, 346: 629-636) ventricles. In addition, 5-HT4 receptors were thought to be localised exclusively in the atrium (Blondel et al., 1998, Journal of Neurochemistry Vol 70(6), 2252-2261, Blondel et al., 1997, FEBS Letters Vol. 412, 465-474).
- A recent publication by Bach et al (2001, Naunyn Schmiedeberg's Arch. Pharmacol, 363; 146-160) however shows that the mRNA encoding 5-HT4 receptors is detectable in all 4 chambers of the normal human heart by RT-PCR. Co-expression of the 5-HT4(a) and 5-HT4(b) variants in both cardiac atrium and ventricle was shown. However, no functional studies of the receptors were reported.
- 5-HT4 receptor antagonists (such as that disclosed by WO 93/02677) have been proposed for use in the treatment of atrial arrhythmias and stroke, in addition to irritable bowel syndrome, gastro-oesophageal reflux disease, anxiety and/or migraine (WO 91/16045, Kaumann 1994 TiPS Vol 15, 451-455).
- No previous studies have suggested any involvement or effect of the 5-HT4 receptor on heart failure, or any effects of heart failure on this receptor.
- As mentioned above, it has now surprisingly been shown that the potential inotropic response (the force of muscular contraction) to 5-HT differs in papillary muscles from non-failing and failing rat heart, and in particular that only papillary muscles from failing rat hearts show a response to 5-HT (see Example 1).
- We have further surprisingly shown that this inotropic effect is mediated through 5-HT4 receptors. The observation that 5-HT4 receptors are functional in failing rat heart muscle, and not in normal rat heart muscle indicates that this induction and signalling may be a novel compensatory mechanism in heart failure. By the term “compensatory mechanism” it is meant that the heart adapts to its reduced ability to function, in an attempt to compensate for decreased pumping. The adaptation, as in this case, and in the case of the β-adrenergic system, may take the form of an adaptation, or induced changes in signalling mechanisms and pathways. Thus, blocking this compensatory mechanism, for example, by using an antagonist of 5-HT4 receptors, presents a novel and hitherto unforeseen treatment modality in combatting heart failure.
- The fact that human papillary muscles taken from patients with different types of heart failure also exhibit an inotropic response to serotonin, that is mediated by 5-HT4 receptors (Example 6) confirms that this effect is not restricted to rats.
- It has also been shown that 5-HT4(b) mRNA levels are increased in left ventricle and in papillary muscle in rats with CHF.
- Thus, in one aspect, the present invention provides the use of 5-HT4 receptor antagonists in the manufacture of a medicament for combatting heart failure.
- Also provided is a method of combatting heart failure in a mammal, said method comprising administering a 5-HT4 receptor antagonist to said mammal. Particularly, an effective amount of said antagonist is administered.
- In still a further aspect, the invention also provides a 5-HT4 receptor antagonist, or a pharmaceutical composition containing such an antagonist for use in combatting heart failure.
- Still further, is provided the use of a 5-HT4 receptor antagonist for combatting heart failure.
- The mechanism by which the inotropic response to 5-HT is induced in heart failure has not yet been elucidated, but in any event, it is not critical to the proposed new therapeutic approach. However, whilst not wishing to be bound by theory, the mechanism of induction of the inotropic response may result from a functional activation of pre-existing inactive receptors whether through a structural or topological change, or release of inhibition. Alternatively the pre-existing receptors may be transported to a location where they can act. The mechanism may alternatively be increased synthesis, or induction, of novel receptors through increased transcription or translation. It is therefore to be understood that “induction” may refer to any mechanism whereby the activity of the 5-HT4 receptor signalling pathway is increased when compared to the activity in a normal (e.g. non-failing) heart.
- In particular, the “induction” includes any mechanism whereby the 5-HT4 receptor mediated inotropic response is induced or increased. An “increase” is preferably or conveniently a statistically significant increase, for example in a test for 5-HT4 receptor mediated response as described in Example 1, or in any other test for inotropic response known in the art or described in the literature.
- The term “heart failure” as used herein includes any condition characterised by impaired cardiac function either due to reduced pump action (systolic dysfunction) or reduced filling (diastolic dysfunction). More particularly, heart failure implies impaired function of the myocardium of the heart. Particularly, chronic forms of heart failure (i.e. chronic heart failure) in general are concerned. Alternatively viewed, a subset of heart failure of particular interest is congestive heart failure (CHF), and especially chronic congestive heart failure (cCHF). However other forms of heart failure are encompassed by the invention. The invention does not however include other heart diseases or conditions which do not come under the general definition of heart failure, as above, such as atrial arrythmias which are excluded from the scope of this invention.
- Thus, heart failure can be defined as a disorder which may result from any condition that reduces the ability of the heart to pump blood. Often the cause is decreased contractility of the myocardium resulting from diminished coronary blood flow (e.g. heart failure caused by coronary artery disease (CAD) or coronary ischemic disease), but failure to pump adequate quantities of blood can also be caused by damage to heart valves, external pressure around the heart, primary cardiac muscle diseases (e.g. idiopathic dilated cardiomyopathy) or any other abnormality which makes the heart a hypoeffective pump. As mentioned above, chronic heart failure is particularly concerned.
- Thus included in the scope of the invention are ischaemic heart disease (ischaemic cardiomyopathy), particularly chronic ischaemic heart disease, chronic non-ischaemic cardiomyopathy including idiopathic dilated cardiomyopathy and cardiomyopathy due to hypertension.
- Cardiac failure may be manifest in either of two ways: (1) by a decrease in cardiac output or (2) by a damming of blood in the veins behind the left or right heart. The heart can fail as a whole unit or either the left side or the right side can fail independently of the other. Either way this type of heart failure leads to circulatory congestion and, as a result is referred to as congestive heart failure (CHF).
- Congestive heart failure can be divided into two phases, acute (short term and unstable) CHF and chronic (long term and relatively stable) CHF. The division between the two is difficult to define precisely, but generally acute CHF is the stage of failure which occurs immediately after heart damage (i.e. has a rapid onset and short course) and is associated with instability in cardiac function and circulation, for example a sudden drop in cardiac output. Providing the acute phase is not so severe as to result in death, the sympathetic reflexes of the body are immediately activated and can compensate for the sudden loss in cardiac function. Such compensation can often be so effective and rapid that it is possible that no noticeable effect on the patient will be felt if a patient remains calm.
- After the first few minutes of an acute heart attack, a prolonged secondary state begins. This is characterized by a retention of fluid by the kidneys and by the progressive recovery of the heart over a period of several weeks to months up until the point at which the cardiac condition stabilises. This phase of stability is known as chronic CHF. Although the heart has compensated and stabilised it is still weak and may become progressively weaker.
- This means therefore that although symptoms vary largely between patients, patients with chronic CHF characteristically have a reduced cardiac function. The most common manifestation of reduced cardiac performance is systolic dysfunction. For example such patients display a reduced left ventricular ejection fraction (LVEF) when compared to a “normal” person who has not suffered from heart failure. In normal persons left ventricular ejection fraction is usually above 60%, while an ejection fraction less than 40% is characterized as systolic dysfunction. Thus, a LVEF of less than 40% is characteristic of reduced heart function in patients with chronic CHF. Less common than systolic dysfunction is diastolic dysfunction in which the ejection fraction is relatively preserved (left ventricular EF>40%) or normal, but where left ventricular filling is reduced.
- Other characteristics of reduced cardiac function such as for example a reduced right ventricular ejection fraction, reduced exercise capacity and impaired haemodynamic variables such as a decreased cardiac output, increased pulmonary arterial pressure and increased heart rate and low blood pressure are also often observed in patients with cCHF.
- The New York Heart Association (NYHA) classification system divides heart disease into four classes, depending on the severity of disease. NYHA class I: Patient with cardiac disease but without resulting limitations of physical activity; Class II: Patient with cardiac disease resulting in slight limitation of physical activity. Class III: Patient with cardiac disease resulting in marked limitation of physical performance. They are comfortable at rest. Class IV: Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present at rest.
- The invention may be used for the treatment of all classes of heart failure but particularly the classes II-IV.
- As alluded to above, heart failure in general may be chronic or acute. Thus, while the acute phase of heart failure (for example CHF) is over relatively quickly, the stability associated with the chronic phase of heart failure (e.g. CHF) can take a matter of months to develop. Generally, a patient exhibiting symptoms of heart failure for greater than 3 months or more preferably greater than 6 months can be regarded as having chronic stable heart failure, providing that no further symptoms of acute (e.g. congestive) heart failure such as angina or evidence of myocardial infarction have occurred during this 3 month or 6 month period.
- As was alluded to briefly above, the chronic heart failure to be treated according to the present invention may result from any cause, e.g. may be the result of a primary disease or may be secondary to another disease. In one preferred embodiment of the invention the chronic heart failure to be treated is secondary to either idiopathic dilated cardiomyopathy (IDCM) and/or coronary ischemic disease (coronary artery disease—CAD).
- Particularly, in a further preferred embodiment, the heart failure to be treated according to the invention is post-infarction heart failure. It will be noted in this regard that the rat model used in Example 1, 2, 4 and 7 is a model of post-infarction heart failure caused by coronary artery ligation, which is a well characterised model of heart failure.
- Other types of heart failure which may be treated according to the invention include heart failure induced by a constantly increased after load, such as hypertensive heart failure. A rat model for this is also available, wherein heart failure is induced by aortic banding. This model has also been used to show that the 5-HT4 receptor mediated effect is not specific to post infarction heart failure (see Example 5).
- The term “combatting” as used herein includes both treatment and prevention.
- The term “5-HT4 receptor antagonist” as used herein includes any agent, i.e. any compound, substance, molecule or composition (or any other agent) which may reduce or prevent any response, for example an inotropic response, to 5-HT in heart failure (i.e. the response (e.g. inotropic response) of the heart, or preferably of the myocardium). Thus the antagonist may be viewed as any agent capable of inhibiting the inotropic response to 5-HT, or any other physiological or biological response to 5-HT. This activity may readily be assessed using any appropriate response test, for example any inotropic response test, available in the art, for example as detailed in Example 1. Thus, an inhibition may be observed as a decrease (e.g. a statistically significant decrease) in the response in question (e.g. inotropic response) in the presence of the agent as compared with the response (e.g. inotropic response) in the absence of the agent (i.e. antagonist).
- Any agent known in the art and/or reported in the literature as an antagonist of 5-HT4 receptors may be used (including inverse agonists and partial agonists etc. which may function as antagonists under particular conditions, e.g. dosages/concentrations etc.).
- Thus, the term “5-HT4 receptor antagonist” as used herein includes any compound, molecule, substance, agent or composition which attenuates the effect of 5-HT on the 5-HT4 receptor. Such antagonism may be competitive or non-competitive. Competitive antagonists bind to the receptor at a region that overlaps with the agonist binding site, thereby preventing the binding of the agonist. The negative log of the molar concentration which at equilibrium would occupy 50% of receptors in the absence of ligand (pKB) is the measure of potency of a competitive antagonist. Non-competitive antagonists bind to a site on the receptors other than the site of agonist binding and prevent agonist binding and/or receptor activation via an allosteric mechanism. In addition, antagonists may be reversible or irreversible. Antagonists may readily be identified by their activity at the 5-HT4 receptor using any suitable assay or test system, conveniently any in vitro system using cells expressing stably or transiently transfected recombinant 5-HT4 receptors or endogenous 5-HT4 receptors, such as those described by Bach et al., (2001, supra).
- Classically, receptor antagonists are small organic compounds and these represent a preferred class of 5-HT4 receptor antagonists for use according to the present invention. However, other “compounds” or “agents” may also be used; so long as they meet the functional criterion of inhibiting an inotropic (or any other) response to 5-HT (e.g. by blocking or inhibiting a 5-HT4 receptor) their chemical or physical nature is unimportant. Thus, for example protein or peptide molecules may be used, which may be natural or synthetic, or derivatives or modifications of natural molecules. One such class of protein/peptide molecules is antibodies and their fragments or derivatives, including synthetic antibody-like molecules. Many such “binding molecules” based on antibodies are known in the art e.g. single chain antibodies, CDR grafted antibodies, chimeric antibodies etc., and all such molecules are included. Alternatively, peptides and other molecular products of display or other (e.g. combinatorial) libraries may be used; the literature describes the synthesis and selection of many such binding molecules or binding entities by such display or other methods, and these may be used, selected to bind to the 5-HT4 receptor.
- Also included are the salts of such compounds, including both organic and inorganic salts (e.g. with alkali and alkaline earth metals, ammonium, ethanolamine, diethanolamine and meglumine, chloride, hydrogen carbonate, phosphate, sulphate and acetate counterions). Appropriate pharmaceutically and/or physiologically acceptable salts are well described in the pharmaceutical literature. In addition, some of these salts may form solvates with water or organic solvents such as ethanol. Such solvates are also included within the scope of this invention.
- 5-HT4 receptor antagonists may also be prepared as pro-drugs according to principles well known in the art (e.g. as compounds which release, or which convert to, the active antagonist form when administered to the patient).
- 5-HT4 receptor antagonists are known in the art and described in the literature (Clark, R. D. in 5-HT4 Receptors in the Brain and Periphery, ed R. Eglen 1998 Springer Verlag and R. G. Landes Company). Any such compounds may be used according to the present invention. Thus, for example 5-HT4 receptor antagonists may be selected from compounds comprising an aromatic ring structure with a hydrogen-bond acceptor as one substituent and a hydrogen-bond acceptor as a second substituent and a tertiary amine spaced with at least three bonds away from the aromatic ring.
- The 5-HT4 receptor antagonists are preferably selected from compounds comprising an aromatic ring to which a carbonyl group is attached, and a basic nitrogen in the appended side chain. An oxygen atom is preferably adjacent to the carbonyl group.
- Representative classes of suitable compounds include benzoate esters, benzoate amides, imidazolopyridines, aryl ketones, indoles, carbazimidamides, phenylcarbamates and phenylureas.
- Further examples of 5-HT4 receptor antagonists that could be used in the invention include: SB203186, 1-piperidinyl-ethyl-1H-indole-3-carboxylate (Parker S G et. al. Naunyn Schmiedebergs Arch Pharmacol. 1995 December; 353(1): 28-35); GR113808, [1-[2-methylsulphonylamino ethyl]-4-piperidinyl]methyl1-methyl-1H-indole-3-carboxylate (Kaumann A J. Br J. Pharmacol. 1993 November; 110(3): 1172-4); SB207710, (1-butyl-4-piperidinyl)methyl 8-amino-7-iodo-1,4-benzodioxan-5-carboxylate (Kaumann A J et. al. Naunyn Schmiedebergs Arch Pharmacol. 1994 May; 349(5): 546-8); SDZ205557, 2-diethylaminoethyl-(2-methoxy-4-amino-5-chloro)benzoate (Lorrain J et. al. Eur J Pharmacol. 1992 Dec. 8; 229(1): 105-8); DAU 6285, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-2,3-dihydro-6-methoxy-2-oxo-1H-benzimidazole-1-carboxylate (Torres G E et. al. J Pharmacol Exp Ther. 1994 October; 271(1): 255-61); RS 39604, 1-[4-amino-5-chloro-2-(3,5-dimethoxybenzyloxy)phenyl]-3[1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]-1-propanone hydrochloride (Leung E et. al. Naunyn Schmiedebergs Arch Pharmacol. 1996 July; 354(2): 145-56); SB 204070, (1-n-butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate (Leung E. et al. supra); SB 207266, N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2-a]indolelocarboxamide hydrochloride (Gaster L M et. al. J. Med Chem. 1995 Nov. 24; 38(24): 4760-3); SB205008, 1-butyl-1-methyl-4-piperidinylmethyl)-8-amino-7-chloro-1,4-ben zodioxan-5-carboxylate iodide (McLean P G and Coupar I M. Naunyn Schmiedebergs Arch Pharmacol. 1995 August; 352(2): 132-40); (1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride (Gaster L M et al. J Med Chem. 1993 Dec. 10; 36(25): 4121-3); N-3389, (endo-3,9-dimethyl-3,9-diazabicyclo[3,3,1]non-7-yl 1H-indazole-3-carboxamide dihydrochloride) (Hagihara K et. al. Eur J Pharmacol. 1994 Dec. 12; 271(1): 159-66); FK1052, [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-4-imidazolyl)methyl]pyrido-[1,2-a]-indole-6(7H)-one hydrochloride] (Kadowaki M et. al. J Pharmacol Exp Ther 1993 July; 266(1): 74-80); ML10375,2-(cis-3,5-dimethylpiperidino)ethyl 4-amino-5-chloro-2-methoxybenzoate (Blondel O et. al. Br J Pharmacol. 1998 October; 125(4): 595-7); RS-23597-190, [3-(piperidine-1-yl)propyl-4-amino-5-chloro-2-methoxybenzoate hydrochloride] (Bonhaus D W et. al. J Pharmacol Exp Ther. 1994 October; 271(1): 484-93); GR125487, (1-[2-[(methyl-sulphonyl)amino] ethyl]-4-piperidinyl-methyl-5-fluoro-2-methoxy-1H-indole-3-carboxylate) (Gale et al 1994 Br. J. Pharmacol., 113, 120P); (3-α-tropanyl)-1H-indazole-3-carboxylic acid (WO91/16045); ICS205-930 (tropisetron) (Dumuis A. et al. (1998), Eur J. Pharmacology 146 187-188); R50595 (FR76530) (Meulemans A L and Schuurkes J A. (1992), Eur J. Pharmacol. 212(1):51-9); RS 100235 (Clark R. D. et al. (1995) Bioorg Med Chem Lett; 5; 2119-2122); RS100302 (Rahme et al., 1999, Circulation 100(9): 1942-4); LY353433, 1-(1-methylethyl)-N-[2-[4-[tricyclo[3.3.1.1 (3,7)]dec−1-ylcarbonyl)amino]-1-piperidinyl]ethyl-1H-indazole-3-carboxamide, (Cohen M. L. et al. J Pharmacol Exp Ther 1996; 277(1): 97-104); RO116-0086, 2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid 1-butyl-piperidin-4-ylmethyl ester hydrochloride salt, (Joubert L. et al., J Biol Chem. 2002, 277: 2250); RO116-1148 (2,3-dihydrobenzo[1,4]-dioxine-5-carboxylic acid 1-butyl-piperidin-4-ylmethyl amide hydrochloride salt) Joubert et al. 2002, supra) A-85380 (WO94/08994); SB205800 (Drug Data Report (1993) 15 10:949); SB 207058 (Exp Opin Invest Drugs (1994) 3(7):767); SB 207226 (Marketletter 22-1 en 22-18 (1995)); SC-53606 (Yang D C et al (1993) J Pharmacol Exp Ther; 266(3):1339-47); SC 56184 (R&D Focus (1993) 2(37)10).
- However other 5-HT4 receptor antagonists may also be used.
- 5-HT4 receptor antagonists are further described in the following patent documents: WO91/16045, WO93/02677, WO93/18036, WO93/05040, WO 93/03725, WO 93/05038, PCT/EP93/03054, PCT/GB93/01895, PCT/EP93/02808, PCT/GB93/02028, PCT/EP93/02775, PCT/EP93/02809, PCT/GB93/02130, PCT/GB94/00172 (all to Smith Kline Beecham plc), EP-A-501322 (Glaxo), U.S. Pat. No. 6,331,401 (Synaptic Pharmaceutical Corporation), US 20020128172 (GlaxoSmithKline), US 20030045452 (GlaxoSmithKline), US 20020019386 (GlaxoSmithKline), EP-A-322973 (GlaxoSmithKline), EP-A-18002 (Sandoz Limited), U.S. Pat. No. 5,872,134 (Smith Kline Beecham), EP-A-387431 (Beecham Group plc), EP-A-201165 (Beecham Group plc), EP-A-201165 (Beecham Group plc), EP-A-234872 (Adria), U.S. Pat. No. 4,859,683 (Rorer), EP-A-307172 (Lilly), U.S. Pat. No. 6,127,379 (Smith Kline Beecham), U.S. Pat. No. 6,002,009 (Boehringer Ingelheim), U.S. Pat. No. 5,929,089 (Synthelabo) and U.S. Pat. No. 5,726,187 (Smith Kline Beecham).
- By definition, as explained above, the 5-HT4 receptor antagonists will inhibit any 5-HT4 receptor mediated action of 5-HT in the failing heart. The antagonist may thus for example inhibit all 5-HT4 receptor mediated actions. By inhibition is meant that the response to 5-HT, for example the inotropic response, when compared to an untreated individual, is reduced. This reduction includes any measurable decrease in a response to 5-HT (e.g. the ventricular inotropic response) in an individual when compared to the 5-HT response (e.g. the ventricular inotropic response) in an individual taken at an earlier time, before treatment. The measurable decrease will preferably be statistically significant. More preferably the measurable decrease will be such that the 5-HT response (e.g. the ventricular inotropic response) is substantially inhibited by the 5-HT4 receptor antagonist. Most preferably the response is blocked. By blocked it is meant that no measurable response (e.g. the inotropic response) to 5-HT is detected in the presence of the 5-HT receptor antagonist.
- Especially preferably the decrease will be associated with the improved cardiac performance of the patient.
- Cardiac performance may be assessed according to methods and practices well known in the art.
- Given the nature of most forms of heart disease it is not to be expected that “treatment” in accordance with the present invention will result in a complete cure of the heart failure in question. Rather, “treatment” in accordance with the present invention includes an improvement or alleviation of any of the symptoms associated with the heart failure and also an improved quality of life for a patient and, ultimately a prolonged lifetime and improved survival. “Treatment” in accordance with the present invention also includes an improvement or increase of the functionality of the heart or, in other words an improvement or increase in cardiac function or performance. In particular, treatment in accordance with the present invention may result in an improvement or increase in any one or more of the symptoms and functional parameters associated with heart failure patients and in particular the following symptoms and parameters of the patient.
- The first symptom and parameter associated with improved cardiac function in heart failure patients is an increase in ventricular ejection fraction and in particular left ventricular ejection fraction (LVEF). This can be assessed by standard methods well known and documented in the art, for example by echocardiography, ECG synchronized gated radionuclide ventriculography (MUGA scan), angiography or magnetic resonance (MR) imaging, and is normally carried out when the subject is at rest. An improvement in LVEF has been found to be associated with improved survival amongst CHF patients (Cintron et al., 1993, Circulation Vol 87, Supplement VI, 17-23). Thus, this is an important and advantageous parameter to be improved in subjects treated in accordance with the present invention. RVEF may also be increased.
- Whilst an improvement of LVEF is particularly important for the overall improvement of heart function, a number of other parameters associated with cardiac performance may be improved in accordance with the present invention. One of these is a significant improvement in overall clinical status and thus clinical performance as evaluated by NYHA functional class. In other words the NYHA functional class of a patient may be reduced after treatment with 5-HT4 antagonists in accordance with the present invention. Such a clinical evaluation may normally be carried out by a trained cardiologist.
- Also an improvement may be seen in exercise capacity of the patients, as measured by peak oxygen uptake and peak work load. As indicated above, a decreased exercise capacity is an inconvenient and potentially dehabilitating symptom of many heart failure patients. Methods for measuring exercise capacity are well known and documented in the art. For example exercise testing can be carried out using an electrically braked bicycle ergometer. An exemplary protocol might consist of a starting work rate of 20 W increasing by 20 W every second minute until exhaustion (defined as an inability to keep the pedalling rate steady at 60 rpm). Oxygen uptake (VO2) can be measured using for example the EOS/SPRINT system. Peak VO2, is taken as the highest VO2 observed.
- Furthermore various improvements in hemodynamic status and echocardiographic variables may also be observed. These are again indicative of improved cardiac function. For example a significant decrease in pulmonary capillary wedged pressure and in pulmonary artery pressure may be observed, together with an increase in peak heart rate, peak systolic blood pressure and mitral velocity deceleration time. Echocardiographic variables may conveniently be measured by echocardiography carried out by a trained cardiologist and haemodynamic variables can conveniently be assessed by right-sided heart catheterization according to standard techniques.
- Another important variable which may be assessed is the plasma level of Nt-proANP. An increased or generally high level of Nt-proANP has been recognised as a marker of cardiac dysfunction. Moreover, levels of Nt-proANP have been shown in the past to correlate with pulmonary artery pressures in CHF and provide important prognostic information in CHF patients (Gottlieb et al., J. Am. Coll. Cardiol. 1989; 13: 1534-1539). Levels of Nt-proANP in a blood sample can be measured in a number of ways well known and documented in the art, for example by radioimmunoassay. Prior to the immunoassay, plasma is separated from a blood sample taken from the patient again by methods well known and documented in the art.
- The above described “improvement” or “increase” in the symptoms and parameters includes any measurable improvement or increase when the parameter in question is compared with the equivalent parameter in a non-treated individual or when the parameter in question is compared with the equivalent parameter in the same individual taken at an earlier time point (e.g. comparison with a “base line” level). Preferably the improvement or increase will be a statistically significant one. Especially preferably the improvement or increase in the symptoms and parameters will be associated with the improved health of the patient concerned and more preferably a prolonged survival.
- Methods of determining the statistical significance of differences in parameters are well known and documented in the art. For example herein a parameter is generally regarded as significant if a statistical comparison using a two-tailed significance test such as a Student t-test or Mann-Whitney U Rank-Sum test shows a probability value of <0.05.
- Thus, a further aspect of the present invention relates to the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for use in the improvement of cardiac function, particularly cardiac function in heart failure.
- In a yet further and more preferred aspect, the present invention relates to the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for use in the increase of ventricular function, particularly preferably left ventricular function (e.g. LVEF), more particularly in heart failure.
- A yet further aspect of the present invention relates to the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for use in the reduction of plasma Nt-proANP levels. As mentioned above, a reduction in the plasma levels of Nt-proANP is an indicator of improved cardiac function and performance. “Reduction” as used herein includes any measurable reduction when the parameter in question is compared with the equivalent parameter in a non-treated individual or when the parameter in question is compared with the equivalent parameter in the same individual taken at an earlier time point (e.g. comparison with a “base line” level). Preferably the reduction is statistically significant as discussed above. Especially preferably the reduction in the levels of Nt-proANP will be associated with an improved feeling of health in the patient concerned and more preferably a prolonged survival.
- Alternatively viewed, the invention provides a method of improving cardiac function in a mammal (for example a mammal with heart failure) which method comprises administering to said mammal a pharmaceutically effective amount of a 5-HT4 receptor antagonist.
- The above described uses and methods are generally carried out on mammals. Any mammal may be treated, for example humans and any livestock or domestic animal, e.g. mice, rats, pigs, cats, dogs, sheep, rabbits, horses, cows or monkeys. However preferably the mammals are humans.
- The 5-HT4 receptor antagonist is conveniently formulated in a pharmaceutical composition for use according to the present invention. Thus, as mentioned above in a further aspect, the present invention also provides a pharmaceutical composition for use in combatting heart failure, said composition comprising a 5-HT4 receptor antagonist together with at least one pharmaceutically acceptable carrier diluent or excipient.
- The appropriate content of active ingredient in such compositions may be determined according to principles and procedures routine in the art and may readily be determined by the skilled practitioner. Thus, for example, the active ingredient in such compositions may comprise from 0.05% to 99% by weight of the formulation, for example from 0.1% to 1.0% or around 0.5%. The concentration of active ingredient in the formulation will depend on the type of formulation. For example, enteral products (e.g. tablets and capsules) can typically have 5% to 50% active ingredients by weight, whereas parenteral formulations usually have a lower concentration of active compound e.g. 0.1% to 3% active ingredient by weight, for example in an injection solution.
- By “pharmaceutically acceptable” is meant that the ingredients must be compatible with other ingredients of the composition as well as physiologically acceptable to the recipient.
- The pharmaceutical compositions may be formulated according to any of the conventional methods known in the art and widely described in the literature. Thus, the active ingredient (i.e. 5-HT4 receptor antagonist) may be incorporated, optionally together with other active substances, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations which are suitable or can be made suitable for subcutaneous, intramuscular, intravenous or any other administration such as powders, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, ointments, sterile injectable solutions, sterile packaged powders, and the like. The pharmaceutical composition comprising the 5-HT4 receptor antagonist may be prepared in a form appropriate for infusion or injection into a patient. Such infusion or injection is preferably intravenous (i.v.) but may also be given subcutaneously (s.c.) or intramuscularly (i.m.).
- Preferably, the compositions may be provided in a form adapted for oral or parenteral administration. Alternative pharmaceutical forms thus include plain or coated tablets, capsules, suspensions and solutions containing the active component optionally together with one or more inert conventional carriers and/or diluents.
- Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, maltose, glucose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable mixtures thereof. The compositions may additionally include lubricating agents, wetting agents, emulsifying agents, suspending agents, preserving agents, sweetening agents, flavouring agents, and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- Solubilizing and/or stabilizing agents may also be used, e.g. cyclodextrins (CD) α, β, γ and HP-β cyclodextrin.
- Suitable doses will vary from patient to patient and can be determined by the physician in accordance with the weight, age and sex of the patient, mode of administration, and the severity of the condition and also the particular antagonist used for treatment. Exemplary unit doses for oral administration contain 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 50 mg), of the active ingredient. The daily dose for oral administration is normally in the range of approximately 0.01 to 10 mg/kg/day, more usually 0.1 to 5 mg/kg/day, for example 0.1 to 2 mg/kg/day. For example a 70 kg adult would receive a daily dose of 1 to 700 mg or 0.7 to 700 mg, more usually 1 to 350 mg or 7 to 350 mg for example 7 to 140 mg. For intravenous or intramuscular administration the doses can be between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, the compound being administered 1 to 4 times a day.
- The improvements seen in patients treated in accordance with the present invention may be immediate (e.g. after a few days), or may be seen after a few weeks or a few months depending on the individual patient. Once the initial improvement is seen, continued improvement over the subsequent weeks and months may also occur. As indicated above, treatment can be continued for as long as is desired or is necessary.
- Use of a 5-HT4 receptor antagonist in accordance with the present invention may be in place of, or preferably in addition to (i.e. in combination with) the use of other drugs for treatment of heart failure. Thus, other drugs known to treat heart failure might be included in the pharmaceutical compositions described above or may be administered separately, in a manner appropriate for the drug concerned.
- Thus, in a further aspect the present invention provides a product comprising (a) a 5-HT4 receptor antagonist and (b) a second drug (e.g. a second agent effective for the treatment of heart failure) as a combined preparation for simultaneous, separate or sequential use in the treatment of heart failure or in improving cardiac function.
- Suitable 5-HT4 receptor antagonists are defined above. Suitable second drugs or agents are well known and documented in the art and include known drugs for use in the treatment of heart disorders, for example diuretics, vasodilators, inotropic drugs such as digoxin, or other compounds such as anticoagulants, β blockers, angiotensin II blockers, angiotensin converting enzyme inhibitors or aldosterone antagonists may be used as discussed above.
- A particularly advantageous combination of 5-HT4 receptor antagonist is with β-blockers.
- The invention will be further described with reference to the following non-limiting Examples with reference to the following drawings in which:
-
FIG. 1 shows the inotropic effect of serotonin in heart failure rats. Original paper recording in a papillary muscle from a representative Chronic heart failure rat. Serotonin (10 μmol/l) induced a positive inotropic response in the presence of atropine, timolol and prazosin. Inset: Development of the inotropic response, expressed as Fmax in percent of individual maximal response, in Chronic heart failure papillary muscles following addition of serotonin to 10 μmol/l. Horizontal error bar represents time±SEM to 50% relative response. The time needed to reach each percentile is the mean value from 10 papillary muscles. -
FIG. 2 shows the inotropic response to serotonin (10 μmol/l) and isoprenaline (100 μmol/l) in papillary muscles from Chronic heart failure and sham-operated rats. a) Increase in development of force expressed as percent above control. b) Representative examples of single recordings of contraction-relaxation cycles in a papillary muscle exposed to serotonin and isoprenaline. The figure shows representative contractions before addition of agonist (_), at maximal steady state inotropic response to 10 μmol/l serotonin ( - - - - ) and at maximal steady state inotropic response to 100 μmol/l isoprenaline ( . . . . ). Ordinate: Development of tension in arbitrary units. Abscissa: Time after initiating stimulus. -
FIG. 3 shows the reversal of the inotropic response to serotonin by cholinergic stimulation. The figure shows the increase in contractile force expressed as percent above control in papillary muscles from Chronic heart failure rats in response to cumulative addition of 10 μmol/l serotonin (5-HT), 30 μmol/l carbachol (CCh) and 1 μmol/l atropine (Atropine). Note that carbachol reversed and atropine restored the inotropic response to serotonin. -
FIG. 4 shows the reversal of the inotropic response to serotonin by the 5-HT4-selective antagonist GR113808. The figure shows representative contraction-relaxation cycles in a papillary muscle from a Chronic heart failure rat before addition of agonist (_), at maximal steady state inotropic response to 10 μmol/l serotonin ( . . . . ) and following reversal by 1 μmol/l GR113808 ( - - - - ). Ordinate: Development of tension in arbitrary units. Abscissa: Time after initiating stimulus. -
FIG. 5 shows that the lack of ketanserin effect eliminates involvement of 5-HT2A-receptors. Concentration-response curves for serotonin in papillary muscles from Chronic heart failure rats in the absence and presence of 0.1 μmol/l ketanserin. Inotropic response was measured as dF/dt and is expressed in percent of maximum in each experiment. The concentration of serotonin needed to reach each percentile was calculated for each experiment according to Ariens and Simonis (1964, Molecular Pharmacology, Vol. 1, New York, Academic Press, 119) and mean values are plotted. Horizontal error bars represent SEM of pEC50 values. -
FIG. 6 shows that the high affinity of GR 113808 confirms involvement of 5-HT4-receptors. Concentration-response curves for serotonin in papillary muscles from Chronic heart failure rats in the absence and presence of 0.5 nmol/l GR 113808. The experiments were performed in the presence of 0.1 μmol/l ketanserin and data were analysed and expressed as inFIG. 5 . -
FIG. 7 shows expression of 5-HT4(b), 5-HT2A and ANP mRNA in left ventricle and papillary muscle of sham treated and CHF rats. Messenger RNA for 5-HT4(b) receptor (upper panels), 5-HT2A receptor (middle panels) and ANP (lower panels) was quantified, and normalised to GAPDH. *CHF vs Sham p<0.01, **CHF vs Sham P<0.05. -
FIG. 8 shows the relationship between the maximum inotropic response to 10 μM serotonin in papillary muscle and infarction size (A) and 5-HT4, 5-HT2A and ANP mRNA levels in non-infarcted left ventricle tissue related to infarction size (B). -
FIG. 9 shows concentration-response curves for serotonin in papillary muscles ofrats 6 weeks after myocardial infarction in the absence and presence of 5 nM SB203186 or 5 nM RS39604. Inotropic response (dF/dt) is expressed in percent of maximum for each papillary muscle. -
FIG. 10 shows representative average contraction-relaxation cycles in a papillary muscle from the heart of a rat withCHF 6 weeks after aortic banding before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. -
FIG. 11 shows representative average contraction-relaxation cycles in a trabecular muscle from an explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. -
FIG. 12 shows representative average contraction-relaxation cycles in a trabecular muscle from an explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. -
FIG. 13 shows maximal inotropic response to β adrenoceptor stimulation in rats with CHF treated for six weeks with SB207266 or placebo. - Animals
- Animals were cared for according to the Norwegian Animal Welfare Act which conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No 85-23, revised 1996). Two rats were kept in each cage and housed in a temperature regulated room with a 12-h day/12-h night cycling and allowed free access to water and food.
- Heart Failure Model Induction of Myocardial Infarction
- Male, Wistar rats (Møllegaard Breeding and Research Centre, Skensved, Denmark), weighing about 320 g were intubated and ventilated with 68% N2O, 29% O2 and 2-3% Isofluran (Abbot Laboratories, USA). An extensive myocardial infarction (MI) was induced by a proximal ligation of the left coronary artery. Six weeks later the rats were anaesthetized and ventilated on the respirator with 2.2% Isofluran. Left ventricular pressures were measured (Sjaastad et al., 2000, J. Appl. Physiol, 89: 1445-1454), and Chronic heart failure rats were included in the study if left ventricular end diastolic pressure (LVEDP) was >15 mm Hg. Typically, the infarct comprised most of the left ventricular free wall and also extended to the apex and the base of the papillary muscle. Echocardiography has previously demonstrated severely depressed myocardial function (Sjaastad et al. 200, supra). The sham-operated animals (SHAM) were subjected to the same surgical procedure but the coronary artery was not ligated.
- Isolated Papillary Muscles
- Hearts were isolated from the anaesthetized animals (see above) and carefully dissected free of connective tissue and transferred to ice cold 0.9% NaCl and weighed. The aorta was cannulated, and the coronaries were perfused at 31° C. with a relaxing solution containing: (mmol/l) NaCl 118.3; KCl 3.0; CaCl2 0.5; MgSO4 4.0; KH2PO4 2.4; NaHCO324.9; glucose 10.0; mannitol 2.2 and equilibrated with 95% O2/5% CO2 at 31° C. (pH 7.4). Posterior left ventricular papillary muscle was ligated
- The muscles were transported to a separate laboratory and mounted in organ baths. In order to prevent contracture of the papillary muscles during transportation and mounting, we used a relaxing solution with a Ca++/Mg++ concentration ratio of 1:8 comparable to that of St. Thomas' Hospital cardioplegic solution. The papillary muscles were mounted in organ baths containing the relaxing solution and allowed to adapt at 31° C. for about 20 minutes before the solution was changed to one containing the following (in mmol/l): NaCl 119.2; KCJ 3.0; CaCl2 2.0; MgSO4 1.2; KH2PO4 2.4; NaHCO3 24.9; glucose 10.0; mannitol 2.22 and equilibrated with 95% O2/5% CO2 at 31° C. (pH 7.4).
- The muscles were field stimulated with alternating polarity at 1 Hz with impulses of 5 msec duration and current about 20% above individual threshold (10-15 mA, determined in each experiment). The isometrically contracting muscles were stretched to the maximum of their length-tension curve. The force was recorded and analysed as previously described (Skomedal et al., 1997, J. Pharmacol. Exp. Ther. 280: 721-729). The muscles were allowed to equilibrate for 90 minutes. When used, prazosin (α1-AR antagonist), timolol (β-AR antagonist), ketanserin (5-HT2A selective antagonist) and GR113808 (5-HT4-selective antagonist) were allowed to act for 90 minutes before addition of agonist. Averaged contraction-relaxation cycles (CRC) were calculated for different experimental periods, and these cycles were used to determine descriptive parameters like maximal development of force (dF/dt)max, time to peak force (TPF) and time to relaxation to 20% level (TR2O). Relaxation time (RT) was calculated as TR2O−TPF. (dF/dt)max was used as an index of contractility. Inotropic responses induced by agonists were expressed by increase in (dF/dt)max. RT was used as index of relaxation. Lusitropic responses were expressed as reduction in RT. Mechanical response at the end of the equilibrium period was used as the control response.
- Experimental Design
- Agonist was added cumulatively or as a single bolus directly to the organ baths and was completely mixed in the solution within 2-3 seconds. The concentration-dependent inotropic and lusitropic responses to 5-HT4-receptor stimulation by serotonin were obtained in the presence of prazosin (1 μmol/l) and timolol (3 μmol/l or 1 μmol/l) atropine (1 μmol/l) and ascorbate (10 μmol/l), respectively. Concentration-response curves for serotonin were obtained by adding serotonin cumulatively in the absence and presence of ketanserin (0.1 μmol/l). Concentration-response curves for 5-HT4-receptor stimulation in the presence of ketanserin were performed in the absence and presence of 0.5 nmol/l GR113808 and the relative shift of the curves was used to calculate the Kb for GR113808. When serotonin was added as a single dose (10 μmol/l) the experiments were performed in the absence of ketanserin. The presence of either antagonist did not influence the basal or maximal function of the muscles with regard to mechanical performance or electrical stimulation threshold (data not shown). The different agonists were added directly to the organ baths in increasing concentrations until supramaximal concentrations of agonist were obtained with respect to maximal inotropic response.
- Calculation and Statistics
- The responses for each concentration of agonist were generally calculated as percent of maximal response. The concentration-response curves constructed from papillary muscle experiment were constructed according to Ariens and Simonis (1964, supra), by estimating centiles (EC10 to EC100) for each single experiment and calculating the corresponding means. This calculation provides mean curves that express the response as fractional response or percent of maximum and display horizontal positioning and the correct mean slope of the curves. The horizontal positioning of the concentration-response curves was expressed as pEC50-values (=−logEC50). Data are expressed as mean±standard error of the mean (SEM) and the number of animals expressed as n. The significance levels of differences were calculated according to Students t-test. P<0.05 is considered statistically significant. The inhibition constants Kb were calculated from the Schild equation, based on the relative shifts of the concentration-response curves for receptor stimulation.
- Drugs
- Serotonin (5-hydroxytryptamine hydrochloride, 5-HT) was from Sigma (St. Louis, Mo., USA). GR 113808 ({1-[2-(methyl-sulphonylamino)ethyl]4-piperidinyl}methyl 1-methyl-1H-indole-3-carboxylate) maleate was from Tocris (Bristol, UK). Ketanserin (3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione) tartrate was from RBI (Natick, Mass., USA). Prazosin hydrochloride, timolol maleate. (−)-isoprenaline hemisulphate, ascorbate, carbamylcholine (carbachol) and atropine sulfate were purchased from Sigma. Stock solutions were prepared in double destilled water and kept at minus 20° C. to avoid oxidation. Further dilutions of the drugs were made fresh daily and kept cool (0-4° C.).
- Results
- Inotropic Effects of Serotonin in Heart Failure Rats
- In the presence of prazosin, atropine and
timolol 10 μmol/l of serotonin elicited a monophasic positive inotropic response not seen in sham-operated animals (n=6) (FIG. 1, 2 a). With a lag phase (diffusion delay) of about 5 seconds the time from addition of serotonin to 50% relative inotropic response was 22±2.0 sec, and to maximal inotropic response 1-2 minutes (FIG. 1 , inset). The serotonin mediated increase in contractile force in papillary muscles from post-MI heart failure rats was 44.5±2.9% (SEM, n=10), comparable to the inotropic effect of 10 μmol/l isoprenaline 60.4±5.8% (or 58.5±7%) (SEM, n=10) (FIG. 2 a). The inotropic responses through the respective receptors were not additive indicating coupling to the same signalling pathway. In sham-operated animals, however, isoprenaline evoked a positive inotropic response of 111.6±8.6% (mean±SEM, n=6) (FIG. 2 a) underlining the attenuation of the mechanical response to β-adrenoceptor stimulation in failing myocardium. - Qualitative Characteristics of the Inotropic Response to Serotonin
- The inotropic response to serotonin induced qualitative changes in the contraction-relaxation cycles (
FIG. 2 b) not observed in sham-operated animals. Time to peak force in the control period was 148.0±3.9 ms (mean±SEM, n=8) and after stimulation by serotonin there was a shortening of the contraction-relaxation cycles with a significant reduction in TPF, TR2O and RT (table 1). These changes reflect a selective increase in relaxation compared to contraction, which is comparable to what is observed during β-adrenoceptor stimulation in myocardial preparations (Skomedal et al. 1997, supra), and consistent with common signalling pathways for these agents. - Influence of Cholinergic Stimulation on the Inotropic Response Induced by Serotonin
- Stimulation of muscarinic acetylcholine receptors is well known to exert a functional antagonism of inotropic effects mediated through Gαs-adenylyl cyclase-pathway and as a pharmacological approach to elucidate the involvement of such a pathway in the serotonin induced inotropic response we stimulated these receptors with carbachol. 10 μmol/l of serotonin exerted a positive inotropic response of 33.7±6.6% (mean±SEM, n=5) above control level. Carbachol (30 μmol/l) reversed the response to 4.8±6.5% (mean±SEM, p<0.01) within 2-3 seconds (or 1-2 minutes) (
FIG. 3 ) and partially reversed TPF, TR2O and RT. Atropine (1 μmol/l) restored the response to 45.1±5.1% (mean±SEM, p>0.06 vs. serotonin alone, 2-tailed paired t-test) and re-established the contraction-relaxation cycle characteristics, suggesting an involvement of the Gαs-adenylyl cyclase-pathway. - Reversal of the Inotropic Response Induced by Serotonin by the 5-HT-Selective Antagonist GR113808
- The qualitative characteristics of the inotropic response to serotonin, its similarity to the inotropic response to isoprenaline and the reversal by carbachol all indicated an involvement of the Gs-adenylyl cyclase-pathway. Three different serotonin-receptors couple to Gs and stimulation of adenylyl cyclase, 5-HT4, 5-HT6 and 5-HT7 (Hoyer et al., 1994, Pharmacol. Rev. 46: 157-203). Of these, the 5-HT4 receptor is known to mediate inotropic and chronotropic effects in human and porcine atrium (Kaumann, 1994, Trends Pharmacol. Sci. 15: 451-455), albeit not in rat (Läer et al., 1998, Br. J. Pharmacol. 123: 1182-1188). We therefore tested whether a 5-HT4-selective serotonin receptor antagonist would block the serotonin-mediated inotropic response in papillary muscle from Chronic heart failure rats. GR113808 is a selective 5-HT4-antagonist with a pKi of 9.2-9.7 (Gale et al., 1994, Br. J. Pharmacol. 111: 332-338), and 1 μmol/l GR113808 completely reversed the inotropic response evoked by 10 μmol/l serotonin (
FIG. 4 ). The shortening of the contraction-relaxation cycles induced by serotonin was also sensitive to GR113808. However, as seen fromFIG. 4 , these serotonin-induced changes were not completely reversed when GR113808 was given subsequent to serotonin. This is a typical finding with cAMP-mediated stimulation of inotropy (Skomedal et al., 1997, supra), and does not detract from the fact that GR113808 was able to fully reverse the effects of serotonin. - Lack of Ketanserin Effect Eliminates Involvement of 5-HT2A Receptors
- To the extent that inotropic effects of serotonin have been demonstrated in the rat heart, these have been confined to the atrium and have been mediated by 5-HT2A-receptors (Laer et al., 1998, supra). To test whether 5-HT2-receptors could also be involved in the inotropic effect of serotonin in papillary muscle from Chronic heart failure rats, we used the 5-HT2A receptor antagonist ketanserin. Ketanserin (0.1 μmol/l) did not shift the concentration-response curve for serotonin to higher concentrations of agonist (pD2-value with ketanserin 7.49±0.08 (SEM, n=5) vs. 7.62±0.06 (SEM, n=6) without, p=0.24, unpaired Students t-test), suggesting that the 5-HT2A-receptor is not involved in the inotropic response to serotonin in papillary muscles from post-MI Chronic heart failure rats (
FIG. 5 ). There was no significant difference between the maximal inotropic responses in the two groups (with and without ketanserin), measured at the top of each concentration-response curve (pooled result 17.5±1.9% (SEM, n=11)). The apparently lower inotropic effect in this experiment compared to that in e.g.FIG. 2 a illustrates a consistently lower inotropic effect in all experiments when measured after a full concentration-response curve as opposed to a direct stimulation with a high concentration (e.g. 10 μmol/l) of serotonin. This difference may reflect desensitisation of the response during the continuous stimulation with increasing concentrations of serotonin, as is done to achieve the concentration-response curves. - High Affinity of GR113808 Documents Involvement of 5-HT4 Receptors
- To provide pharmacological evidence for the involvement of 5-HT4 receptors, the shift of the concentration-response curve to serotonin by GR113808 was determined. The experiment was performed in the presence of 0.1 μmol/l ketanserin to block 5-HT2A receptors, if present. The concentration-response curves to serotonin in the absence and presence of 0.5 nmol/l GR113808 were essentially parallel with pEC50-values of 7.62±0.06 (SEM, n=6) and 7.32±0.06 (SEM, n=6, p<0.005), respectively (
FIG. 6 ), with no difference in the maximum inotropic response induced by serotonin between the groups (pooled average 18.7±2.4% (SEM, n=12)). The corresponding GR113808 inhibition constant (Kb) calculated from the Schild equation was 0.5 nmol/l, corresponding to a pKb value of 9.3. Since GR113808 displays at least 1000-fold selectivity for the 5-HT4 receptor over all other known receptors, this provides strong evidence for a 5-HT4 receptor-mediated inotropic response to serotonin in papillary muscle from Chronic heart failure rats.TABLE 1 Qualitative characteristics of the contraction- relaxation cycles (CRC) in Chronic heart failure and sham-operated animals before and after subsequent addition of serotonin (10 μmol/l) and isoprenaline (100 μmol/l), respectively. Control 5-HT 5-HT ISO Iso (ms) (ms) (% of control) (ms) (% of control) Sham n = 6 TPF 125.1 ± 5.5 123.7 ± 5.5 99.0 ± 0.8 109.3 ± 2.7 87.4 ± 2.3 TR20 233.6 ± 11.2 231.0 ± 11.0 99.0 ± 0.7 174.0 ± 4.9 74.5 ± 1.7 RT (TR20 − TPF) 108.4 ± 6.2 107.3 ± 5.9 99.0 ± 0.5 75.0 ± 2.5 69.4 ± 3.2 CHF n = 10 TPF 148 ± 3.9 134 ± 3.5 90.5 ± 1.4 123.1 ± 1.6 83.2 ± 1.7 TR20 254.3 ± 6.3 224.6 ± 5.4 88.3 ± 1.5 204.1 ± 2.9 80.3 ± 1.9 RT (TR20 − TPF) 106.3 ± 2.5 90.6 ± 2.2 85.2 ± 1.5 81.0 ± 1.8 76.2 ± 1.8
Values are mean ± SEM of average results from 20-40 CRC in each group of papillary muscles.
TPF = Time to peak force
TR2O = Time to relaxation to 20% level
RT = Relaxation time
- Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) to Examine 5-HT4 Receptor mRNA Induction in CHF
- Non-infarcted left ventricle tissue (30-50 mg, mainly septum), collected immediately after removal of the papillary muscle, or papillary muscle (15-30 mg including some left ventricular wall) collected after completion of functional analyses, stored in RNAlater (Ambion) until use, was flash frozen and reduced to powder under liquid nitrogen. Total RNA was isolated from tissue powder homogenized in 1 ml TRIZOL (Invitrogen), followed by mRNA extraction (Bach et al. 2001 supra) and oligo-dT-primed first strand cDNA synthesis (Medhurst et al. 2001 Brain Res Mol Brain Res 90: 125-134). A standard curve with 5-300 ng mRNA was made to control for reverse transcription and PCR quantification.
- Sets of primers (targeted to intron/exon boundaries to avoid genomic DNA signals) and probes (Double-Dye Oligonucleotide, Eurogentec, 5′-labeled with the fluorescent reporter dyes FAM (5-HT4(b), GI:924649 (Gerald et al. 1995 EMBO J. 14: 2806-2815) and 5-HT2A, GI:207067 (Julius et al. 1990 PNAS USA 87: 928-932)), JOE (Eurogentec; glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GI:10190788)) or Yakima Yellow (YY; Eurogentec; atrial natriuretic peptide (ANP; GI:55711)) and quenched with TAMRA (5-HT4(b), 5-HT2A and GAPDH) or Dark Quencher (DQ; Eurogentec; ANP)) for quantitative PCR were designed as described (Bustin et al. 2000 J. Mol Endocrinol 25: 169-193). The names and sequences of upper (U) and lower (L) primers and probes (P) used were (5′-3′): 5-HT4(b): ON283(U), CATGTGCATAGGTATACAGTGGAATGT; ON284 (L), GCAGCCACCAAAGGAGAAGTT; TM14(P), FAM-CCATCTGCTGCCAGCCTTTGGTCTATAGGA-TAMRA; 5-HT2A: ON273(U); TTCACCACAGCCGCTTCAA; ON274(L), ATCCTGTAGTCCAAAGACTGGGATT; TM9(P), FAM-ATGGATATACCTACAGATATGGTCGTCCACACGGCAAT-TAMRA; ANP: ON285(U), ATCTGATGGATTTCAAGAACC; ON286(L), CTCTGAGACGGGTTGACTTC; TM15(P) YY-CGCTTCATCGGTCTGCTCGCTCA-DQ; GAPDH: ON279(U), CCTGCACCACCAACTGCTTA; ON290(L), GGCATGGACTGTGGTCATGA; TM12(P), JOE-TGGCCAAGGTCATCCATGACAACTTTG-TAMRA.
- Quantitative RT-PCR (Medhurst et al. supra) was done in 25 μl reactions with TaqMan Universal PCR Master Mix (Applied Biosystems) containing 5 mM Mg2+, 300 nM of each primer, 200 nM probe and long template cDNA. GAPDH was quantified separately for normalization with 0.1 ng cDNA template. Raw data were collected and analyzed with Sequence Detector Software (SDS version 1.7; Applied Biosystems) (Bustin et al. 2000, supra). Results are expressed as mean±SEM from n animals. P<0.05 was considered statistically significant (nonparametric Mann-Whitney test).
- Induction of 5-HT4(b) Receptor mRNA in CHF
- Quantitative RT-PCR was used to determine the level of mRNA encoding 5-HT4(b) receptor, 5-HT2A receptor, and the heart failure marker ANP normalized to the level of GAPDH mRNA. In left ventricle and papillary muscle, respectively, 5-HT4(b) mRNA levels were four and 18-fold higher in CHF vs. Sham, whereas 5-HT2A mRNA levels were unchanged and ANP mRNA levels increased (
FIG. 7 ). The ratio between normalized 5-HT4(b) and 5-HT2A mRNA levels was increased in CHF in both left ventricle and papillary muscle, confirming increased 5-HT4(b) mRNA level relative to 5-HT2A, independent of GAPDH (Table 2). - The Maximum Inotropic Response to Serotonin and 5-HT4(b) Receptor mRNA Related to Infarction Size.
- In papillary muscles from MInf rats i.e. rats in which symptoms of CHF were not obtained, despite having undergone surgery to induce myocardial infarction, serotonin (10 μM) elicited an inotropic response qualitatively similar to the response observed in CHF animals. The magnitude of the response correlated positively with infarction size up to 30-40% of the inner myocardial surface in MInf animals (
FIG. 8A ). In MInf hearts with infarct size 30-40% the inotropic effect was of the same magnitude as in CHF hearts which all had infarct size >40%. A positive correlation with infarction size was also observed for 5-HT4(b) and ANP mRNA expression, whereas 5-HT2A mRNA levels were unchanged (FIG. 8B ). These findings suggest a gradual transition related to the extent of myocardial changes secondary to the infarction.TABLE 2 Ratio of 5-HT4(b) receptor mRNA to 5-HT2A receptor mRNA Sham CHF Left ventricle 0.87 ± 0.33 (n = 7) 3.20 ± 1.09 (n = 11)* Papillary muscle 0.85 ± 0.64 (n = 4) 7.48 ± 2.44 (n = 5)†
To test the observation of increased 5-HT4(b) receptor level independent of GAPDH the ratio of normalized 5-HT4(b) receptor mRNA to normalized 5-HT2A receptor mRNA was calculated.
*CHF vs. Sham p < 0.06;
†CHF vs. Sham p < 0.05
- The inotropic response to serotonin in papillary muscle from 6 week post myocardial infarction rats was measured in the presence of several chemically different 5-HT4 receptor antagonists, as described above.
- The 5-HT4 antagonists SB203186 and RS39604, each added at 5 nM, block the inotropic response to serotonin in 6 week post MI rats with blocking potencies corresponding to their known affinities at 5-HT4 receptors. The figure shows concentration-response curves for serotonin in papillary muscles of
rats 6 weeks after myocardial infarction in the absence and presence of 5 nM SB203186 or 5 nM RS39604. Inotropic response (dF/dt) is expressed in percent of maximum for each papillary muscle. - The pEC50 value for serotonin in the absence of blocker was 7.25±0.2. The pEC50 value for serotonin in the presence of 5 nM SB203186 was 6.39, corresponding to a pKb value of 9.1. The pEC50 value for serotonin in the presence of 5 nM RS39604 was 6.26, corresponding to a pKb value of 9.2. This is consistent with the inotropic response to serotonin being mediated via 5-HT4 receptors.
- 5-HT4 Receptor-Mediated Inotropic Responses in Rat Hypertensive Heart Failure
- A second model of heart failure was then used to study the 5-HT4 receptor-mediated inotropic effect of serotonin; namely a model of rat hypertensive heart failure. This study uses a rat model of heart failure obtained by aortic banding. In this model, the heart failure is induced by a constantly increased afterload, somewhat reminiscent of human hypertensive heart failure. This study was performed to clarify whether it is the heart failure as such, or the cardiac infarction preceding the heart failure that underlies the induction of 5-HT4 receptors in the post-infarction model.
- Trans-aortic constriction (aortic banding) of the ascending aorta was induced in 200 g male Wistar rats under anaesthesia, induced by 63% N2O, 32% O2 and 5% Isoflurane and maintained by 66% N2O, 33% O2 and 1-2% Isoflurane. A right-sided thoracotomi was performed through a 3-4 cm long cutaneous incision, the pericardium was opened and the ascending aorta identified and dissected free of surrounding tissue. A ligature was knit around the ascending aorta and a metal probe with diameter 0.9 mm. The metal probe was then removed. The result was a constriction of the ascending aorta with internal diameter about 0.9 mm. The thorax was then closed with 3-0 silk sutures and the skin closed with Dexon 1 sutures. The animals received post-operative analgesia with buprenorphine 0.09 mg subcutaneously and were allowed to wake up in a 30° C. environment. After six weeks the animals were again placed under anaesthesia as during the primary surgery, and an echocardiographic examination was performed. Finally the thorax was opened and the heart was removed for preparation of posterior left ventricular papillary muscles as described (Sjaastad et al. 2003 Acta physiol Scand 177: 449-458). The rat was considered to have CHF.
- Papillary muscle was extracted from a
CHF rat 6 weeks after aortic banding as described above. Posterior left ventricular papillary muscle was prepared, mounted in organ bath, equilibrated and field stimulated at 1 Hz (Sjaastad et al. 2003 supra), and the contraction-relaxation cycles (CRCs) were recorded and analysed as previously described (Skomedal et al. 1997, J. Pharmacol Exp Ther 280: 721-729) (Sjaastad et al., 2003, supra) with respect to maximal developed force (Fmax), maximal development of force (dF/dt)max, time to peak force (TPF), time to relaxation to 20% level (TR20) and relaxation time (RT=TR20−TPF). The experiment was performed in the presence of blockers (added 90 min prior to serotonin) of adrenergic and muscarinic cholinergic receptors (prazosin 1 μM, timolol 1 μM, atropine 1 μM). -
FIG. 10 shows representative average contraction-relaxation cycles in a papillary muscle from the heart of a rat withCHF 6 weeks after aortic banding before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. Serotonin (10 μM) elicited a positive inotropic response comparable in magnitude and characteristics to the positive inotropic response to 100 μM isoproterenol (enough to surmount the blockade by 1 μM timolol). The positive inotropic response to serotonin was reversed by 1 μM of the 5-HT4 antagonist GR113808, indicating that the response is mediated through 5-HT4 receptors. - This shows that this model of heart failure in rats also causes the appearance of a 5-HT4 receptor-mediated inotropic response to serotonin, indicating that this finding is general for heart failure as such, at least in rats.
- 5-HT4 Receptor-Mediated Inotropic Effect of Serotonin in Human Heart
- To study the 5-HT4 receptor-mediated inotropic response to serotonin in human heart, trabecular muscle from a post-infarct human heart and a human heart with heart failure due to dilated cardiomyopathy was used.
-
FIG. 11 shows representative average contraction-relaxation cycles in a trabecular muscle from the explanted post infarct human heart before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. - The heart was explanted from a patient who had survived a small myocardial infarction and died in hospital from subarachnoidal haemorrhage. Trabecular muscles were prepared, mounted in organ baths, equilibrated and field stimulated at 1 Hz (Skomedal et al., 1997, supra) and the contraction-relaxation cycles (CRCs) were recorded and analysed as previously described (Skomedal et al., 1997, supra) with respect to maximal developed force (Fmax), maximal development of force (dF/dt)max, time to peak force (TPF), time to relaxation to 20% level (TR20) and relaxation time (RT=TR20−TPF). The experiment was performed in the presence of blockers (added 90 min prior to serotonin) of adrenergic and muscarinic cholinergic receptors (prazosin 1 μM, timolol 1 μM, atropine 1 μM).
- As seen in
FIG. 11 , serotonin (10 μM) elicited a positive inotropic response amounting to about 10% of the positive inotropic response to 100 μM isoproterenol (enough to surmount the blockade by 1 μM timolol). The positive inotropic response to serotonin was reversed by 1 μM of the 5-HT4 receptor antagonist GR113808, indicating that the response is mediated through 5-HT4 receptors. - A heart was also explanted from a patient who had received a heart transplant due to heart failure from dilated cardiomyopathy. Trabecular muscles were prepared and the contraction-relaxation cycles (CRCs) were recorded and analysed as described above. In addition to the presence of blockers as above, the positive inotropic responses to serotonin and isoproterenol were enhanced by the presence of the phosphodiesterase inhibitor IBMX (isobutyl-methyl-xanthine; 35 μM).
-
FIG. 12 shows representative average contraction-relaxation cycles in a trabecular muscle from this explanted human heart before addition of agonist, at maximal steady state inotropic response to 10 μM serotonin, following reversal of the serotonin response with 1 μM GR113808 and at maximal steady state inotropic response to 100 μM isoproterenol. - As seen in the figure, serotonin (10 μM) elicited a positive inotropic response amounting to about 32% of the positive inotropic response to 100 μM isoproterenol (enough to surmount the blockade by 1 μM timolol). The positive inotropic response to serotonin was reversed by 1 μM of the 5-HT4 receptor antagonist GR113808, indicating that the response is mediated through 5-HT4 receptors.
- This shows that the presence of an inotropic response through 5-HT4 receptors in the failing heart is also seen in humans.
- Effect of Treatment of Post-Infarction Congestive Heart Failure (CHF) Rats with a 5-HT4 Antagonist.
- An extensive myocardial infarction (MI) was induced in 320 g male Wistar rats under anaesthesia (68% N2O, 29% O2 and 2-3% Isofluran) by a proximal ligation of the left coronary artery (Sjaastad et al. 2003, supra). Three days later, rats were included in the study if the rats had both clinical signs of congestive heart failure (tachypnoe and forced ventilation) and a large myocardial infarction as verified by echocardiography. Rats included in the study were randomized blindly to placebo or treatment.
- Under anesthesia with 75 μg/kg Fentanyl (Janssen Pharmaceutical) and 3.75 mg/kg Midazolam (Roche) s.c., as well as local anesthesia with Xylocaln 1% around the incision, the rats received subcutaneous implantation of 2 ml Alzet miniosmotic pumps (Alza, Palo Alto, Calif.) containing solvent (100 μM ascorbic acid, 50 μM EDTA in water; placebo group) or solvent containing 50 mM of the 5-HT4 antagonist SB207266 (treatment group). The pumps were replaced with new pumps after three weeks to obtain a total treatment time of six weeks.
- After six weeks of treatment, the animals were again placed under Isofluran anaesthesia (68% N2O, 29% O2 and 2-3% Isofluran) with temperature control for echocardiographic and hemodynamic measurements, followed by euthanasia. Posterior left ventricular papillary muscles were then prepared, mounted in organ baths, equilibrated and field stimulated at 1 Hz (Sjaastad et al., 2003 supra) and the contraction-relaxation cycles (CRCs) were recorded and analysed as previously described with respect to maximal developed force (Fmax), maximal development of force (dF/dt)max, time to peak force (TPF), time to relaxation to 20% level (TR20) and relaxation time (RT=TR20−TPF).
- The experiments were performed in the presence of blockers (added 90 min prior to agonist) of α-adrenergic and muscarinic cholinergic receptors (prazosin 1 μM, atropine 1 μM). Isoproterenol was added to the organ bath cumulatively and the maximal positive inotropic response to isoproterenol was calculated for each animal.
- The results are shown in
FIG. 13 and indicate a trend towards normalisation of myocardial function, as judged by the trend towards normalisation of the CHF-induced reduction of maximal inotropic response to β-adrenoceptor stimulation, by treatment with the 5-HT4 antagonist SB207266. - Furthermore, in CHF, the duration of the contraction-relaxation cycle is prolonged, due to changes in myofilament composition. Therefore, the duration of the contraction-relaxation cycle can be used as an additional parameter of the degree of myocardial dysfunction. Our preliminary data from treatment with the 5-HT4 antagonist SB207266 also show a trend towards normalisation of this parameter of myocardial dysfunction (data not shown).
- Tablets (Oral) for Treatment and Prophylaxis of Heart Failure
GR113808 (as hydrochloride salt) 10.95 g lactose 157 g microcrystalline cellulose 30 g magnesium stearate BP 2.05 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose, microcrystalline cellulose and magnesium stearate. The resulting mixture is pressed into tablets. Tablet weight is 200 mg and each tablet contains 10 mg GR113808.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure
SB207266(as hydrochloride salt) 5.5 g Atenolol 25 g lactose 169.5 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose. The mixture is filled into gelatin capsules (200 mg) using suitable machinery. Each capsule contains 5 mg SB207266 and 50 mg atenolol.
- Solution for Injection for Treatment and Prophylaxis of Heart Failure
SB207266(as hydrochloride salt) 10.9 g sodium chloride q.s. water for injection ad. 10 litre - SB207266 (as hydrochloride salt) and sodium chloride are dissolved in water for injection to form an isotonic solution. The mixture is filled into vials (10 ml) with rubber stoppers and sterilised by heating in an autoclave for 20 minutes at 121 degrees centrigade. Each vial contains 10 ml and 1 mg SB207266 per ml.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure
SB207266(as hydrochloride salt) 5.5 g metoprolol tartrate 50 g lactose 144.5 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose. The mixture is filled into gelatin capsules (200 mg) using suitable machinery. Each capsule contains 5 mg SB207266 and 50 mg metoprolol tartrate.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure
SB207266(as hydrochloride salt) 5.5 g enalapril maleate 10 g lactose 184.5 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose. The mixture is filled into gelatin capsules (200 mg) using suitable machinery. Each capsule contains 5 mg SB207266 and 10 mg enalapril maleate.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure
SB207266(as hydrochloride salt) 5.5 g losartan potassium 50 g lactose 169.5 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose. The mixture are filled into gelatin capsules (200 mg) using suitable machinery. Each capsule contains 5 mg SB207266 and 50 mg losartan potassium salt.
- Capsules (Oral) for Treatment and Prophylaxis of Heart Failure (5HT-4 Receptor Antagonist Plus α/β-Blocker)
SB207266(as hydrochloride salt) 5.5 g carvedilol 12.5 g lactose 182 g - The active ingredients are passed through a 24 mesh sieve and blended with lactose. The mixture is filled into gelatin capsules (200 mg) using suitable machinery. Each capsule contains 5 mg SB207266 and 12.5 mg carvedilol.
- Suppositories for Treatment and Prophylaxis of Heart Failure
GR113808(as hydrochloride salt) 16.5 g Glyceride mixture of fatty acid 193.5 g - GR113808 salt is milled down to a particle size of approximately 20 microns. A suspension of the salt is prepared in molten glyceride of fatty acid and filled into suppository moulds. The weight of each suppository is 200 mg with unit dose of 15 mg GR113808.
Claims (35)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/372,592 US8829028B2 (en) | 2002-05-16 | 2009-02-17 | 5-HT4 receptor antagonists for the treatment of heart failure |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0211230.8 | 2002-05-16 | ||
GBGB0211230.8A GB0211230D0 (en) | 2002-05-16 | 2002-05-16 | Treatment of heart failure |
PCT/GB2003/002134 WO2003097065A1 (en) | 2002-05-16 | 2003-05-16 | 5-ht4 receptor antagonists for the treatment of heart failure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/372,592 Continuation US8829028B2 (en) | 2002-05-16 | 2009-02-17 | 5-HT4 receptor antagonists for the treatment of heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060094715A1 true US20060094715A1 (en) | 2006-05-04 |
Family
ID=9936797
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/514,386 Abandoned US20060094715A1 (en) | 2002-05-16 | 2003-05-16 | 5-Ht4 receptor antagonists for the treatment of heart failure |
US12/372,592 Expired - Fee Related US8829028B2 (en) | 2002-05-16 | 2009-02-17 | 5-HT4 receptor antagonists for the treatment of heart failure |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/372,592 Expired - Fee Related US8829028B2 (en) | 2002-05-16 | 2009-02-17 | 5-HT4 receptor antagonists for the treatment of heart failure |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060094715A1 (en) |
EP (1) | EP1503764B1 (en) |
AT (1) | ATE454153T1 (en) |
AU (2) | AU2003227949B2 (en) |
CA (1) | CA2485600C (en) |
DE (1) | DE60330857D1 (en) |
DK (1) | DK1503764T3 (en) |
ES (1) | ES2339234T3 (en) |
GB (1) | GB0211230D0 (en) |
HK (1) | HK1072012A1 (en) |
WO (1) | WO2003097065A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2903657A1 (en) | 2013-02-27 | 2014-09-04 | Shionogi & Co., Ltd. | Indole and azaindole derivatives each having ampk-activating activity |
US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
EP3113777A4 (en) * | 2014-03-04 | 2017-09-06 | The Children's Hospital of Philadelphia | Methods for managing care of patients predisposed to progressive mitral valve diseases |
US20170296506A1 (en) * | 2016-04-13 | 2017-10-19 | Board Of Regents Of The University Of Nebraska | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
CN115487175A (en) * | 2019-09-20 | 2022-12-20 | 深圳信立泰药业股份有限公司 | Use of complexes of angiotensin II receptor antagonist metabolites and NEP inhibitors for the treatment of heart failure |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859683A (en) * | 1988-02-04 | 1989-08-22 | Rorer Pharmaceutical Corporation | Certain benzoxepins and their pharmaceutical compositions and methods |
US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5196547A (en) * | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5219850A (en) * | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5726187A (en) * | 1992-10-16 | 1998-03-10 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists |
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5872134A (en) * | 1993-05-22 | 1999-02-16 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
US5929089A (en) * | 1995-11-09 | 1999-07-27 | Synthelabo | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands |
US5990159A (en) * | 1996-02-15 | 1999-11-23 | Janssen Pharmaceutica, N.V. | Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
US6002009A (en) * | 1995-03-14 | 1999-12-14 | Boehringer Ingelheim Italia, S.P.A. | Di-substituted 1,4-piperidine esters and amides having 5-HT4 antagonistic activity |
US6100339A (en) * | 1994-11-21 | 2000-08-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Curable resin and resin composition comprising the same |
US6127379A (en) * | 1993-02-01 | 2000-10-03 | Smithkline Beecham P.L.C. | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
US6255319B1 (en) * | 1997-04-18 | 2001-07-03 | Sanofi-Synthelabo | 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands |
US6331401B1 (en) * | 1992-12-24 | 2001-12-18 | Synaptic Pharmaceutical Corporation | Uses of the 5-HT4 receptor |
US6331631B1 (en) * | 1996-09-11 | 2001-12-18 | Smithkline Corporation P.L.C. | Preparation of 1-butyl-4-piperidinylmethylamine |
US20020128172A1 (en) * | 1991-12-21 | 2002-09-12 | Smithkline Beecham Plc | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
US20030032640A1 (en) * | 2000-08-08 | 2003-02-13 | Buxton Philip Christopher | Novel composition |
US20030092699A1 (en) * | 2001-10-22 | 2003-05-15 | Chikara Uchida | Imidazopyridine compounds as 5-HT4 receptor modulators |
US6583294B2 (en) * | 1998-07-16 | 2003-06-24 | Smithkline Beecham P.L.C. | Process for the preparation of an indole derivative |
US20040122043A1 (en) * | 2002-09-20 | 2004-06-24 | Pfizer Inc | Imidazopyridine compounds as 5-HT4 receptor agonists |
US20050075335A1 (en) * | 2002-02-14 | 2005-04-07 | Buxton Philip Christopher | Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation |
US20050149580A1 (en) * | 1994-05-06 | 2005-07-07 | Ryuichi Hattori | Data processing apparatus and network system that outputs quality of service information to a user |
US6979690B2 (en) * | 2002-01-07 | 2005-12-27 | Pfizer Inc. | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3061860D1 (en) | 1979-04-24 | 1983-03-17 | Marcel Jozefonvicz | Process for the determination of proteases and antiproteases |
US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
EP0405617A3 (en) | 1985-03-14 | 1992-11-25 | Beecham Group P.L.C. | Medicaments for the treatment of anxiety |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
ZA886585B (en) | 1987-09-08 | 1990-05-30 | Lilly Co Eli | Specific 5-ht,antagonists |
CA1317940C (en) | 1987-09-25 | 1993-05-18 | Georges H. P. Van Daele | Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
NZ227394A (en) | 1987-12-24 | 1992-04-28 | Duphar Int Res | Preparation of optically active alcohols |
JP2643274B2 (en) | 1988-04-08 | 1997-08-20 | 三菱化学株式会社 | Imidazo [1,2-a] pyridine derivative |
EP0387431A1 (en) | 1989-03-14 | 1990-09-19 | Beecham Group Plc | Imidazole derivatives, process for their preparation and their pharmaceutical use |
AU6062590A (en) | 1989-07-07 | 1991-02-06 | Schering Corporation | Pharmaceutically active compounds |
GB9009389D0 (en) * | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
GB9103862D0 (en) | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
US5492919A (en) | 1991-08-03 | 1996-02-20 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
WO1993003725A1 (en) | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
WO1993005040A1 (en) | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Azabicyclic compounds as 5-ht4 receptor antagonists |
HUT70154A (en) | 1991-09-12 | 1995-09-28 | Smithkline Beecham Plc | 5-ht4 receptor antagonists and pharmaceutical compositions containing them |
GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
US5708174A (en) | 1992-03-12 | 1998-01-13 | Smithkline Beecham P.L.C. | Heterocyclic-esters or -amides used as 5-HT4 receptor antagonists |
AP401A (en) | 1992-03-12 | 1995-08-29 | Smithkline Beecham Plc | Condensed indole derivatives as 5H4-receptor antagonists. |
GB9219163D0 (en) | 1992-09-10 | 1992-10-28 | Smithkline Beecham Plc | Pharmaceuticals |
MX9305947A (en) | 1992-09-29 | 1994-06-30 | Smithkline Beecham Plc | ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
GB9221468D0 (en) | 1992-10-13 | 1992-11-25 | Smithkline Beecham Plc | Pharmaceuticals |
MX9306311A (en) | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
GB9301660D0 (en) | 1993-01-28 | 1993-03-17 | Smithkline Beecham Plc | Pharmaceuticals |
TW282460B (en) | 1993-12-28 | 1996-08-01 | Yamanouchi Pharma Co Ltd | |
CA2186623A1 (en) | 1994-03-30 | 1995-10-21 | Takeshi Kawakita | Benzoic acid compound and use thereof as medicine |
AU6856094A (en) | 1994-06-01 | 1995-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Oxadiazole derivative and medicinal composition thereof |
AU3192295A (en) | 1994-08-11 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition containing the same |
ES2103675B1 (en) | 1995-01-10 | 1998-07-01 | Almirall Lab | NEW PIPERIDINES REPLACED. |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
JPH0967347A (en) | 1995-08-30 | 1997-03-11 | Dainippon Pharmaceut Co Ltd | Cyclic amine derivative and medicinal composition containing the same |
JP2000504014A (en) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | Farnesyl-protein transferase inhibitor |
EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
IL128499A (en) | 1996-08-16 | 2002-11-10 | Smithkline Beecham Plc | PROCESS FOR PREPARATION OF N-(1-n-BUTYL-4-PIPERIDYL) METHYL]-3, 4-DIHYDRO-2H-[1, 3] OXAZINO [3, 2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND THE NOVEL ALKYL-3, 4-DIHYDRO-2H-[1, 3]-OXAZINO [3, 2-a] INDOLE-10-CARBOXYLATE INTERMEDIATE THEREOF |
FR2752736B1 (en) | 1996-08-30 | 1998-10-23 | Chu Rouen | USE OF 5-HT4 ANTAGONISTS IN THE REGULATION OF CORTICOSTEROID SECRETION |
JPH10203987A (en) | 1997-01-28 | 1998-08-04 | Dainippon Pharmaceut Co Ltd | Agent containing (r)-1-ethyl-4-methylhexahydro-1h-1,4-diazepine derivative as active component and effective for suppressing vomition induced by morphine-like agent |
NZ525108A (en) | 1998-03-31 | 2005-02-25 | Acadia Pharm Inc | Compounds with activity on muscarinic receptors |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
GB9815483D0 (en) | 1998-07-16 | 1998-09-16 | Smithkline Beecham Plc | Pharmaceuticals |
GB9815481D0 (en) | 1998-07-16 | 1998-09-16 | Smithkline Beecham Plc | Pharmaceuticals |
JP4032566B2 (en) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | Light emitting element |
AU5406399A (en) * | 1999-08-27 | 2001-03-26 | Qingdao Synergy Technology Appliance Co., Ltd. | The method for manufacturing vacuum glazing and its application mechanical system |
JP2004505930A (en) * | 2000-08-07 | 2004-02-26 | ラボラトワール・グラクソスミスクライン・ソシエテ・パール・アクシオン・シンプリフィエ | Use of a 5HT4 receptor antagonist in the manufacture of a medicament for the prevention or treatment of atrial fibrillation |
ES2294012T3 (en) | 2000-08-08 | 2008-04-01 | Smithkline Beecham Plc | PHARMACEUTICAL COMPOSITION THAT INCLUDES A CONDENSED INDOL COMPOUND. |
ATE307812T1 (en) * | 2001-10-22 | 2005-11-15 | Pfizer | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS |
US20070065801A1 (en) | 2003-05-21 | 2007-03-22 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4) |
PT1664036E (en) | 2003-09-03 | 2012-02-16 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
EP1701951B1 (en) | 2003-12-23 | 2010-02-10 | Serodus AS | Modulators of peripheral 5-ht receptors |
ES2344568T3 (en) | 2004-01-07 | 2010-08-31 | Aryx Therapeutics, Inc. | STEREOISOMERAL COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS AND THE CENTRAL NERVOUS SYSTEM. |
WO2006038351A1 (en) * | 2004-09-30 | 2006-04-13 | Sharp Kabushiki Kaisha | Crystalline semiconductor film and method for manufacturing the same |
WO2007007072A1 (en) | 2005-07-07 | 2007-01-18 | Bio-Medisinsk Innovasjon As | 5-htx modulators |
WO2007010390A1 (en) | 2005-07-22 | 2007-01-25 | Pfizer Japan Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
WO2007149929A1 (en) | 2006-06-23 | 2007-12-27 | Aryx Therapeutics, Inc. | Piperidine derivatives for the treatment of gastrointestinal and cns disorders |
JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB |
-
2002
- 2002-05-16 GB GBGB0211230.8A patent/GB0211230D0/en not_active Ceased
-
2003
- 2003-05-16 DE DE60330857T patent/DE60330857D1/en not_active Expired - Lifetime
- 2003-05-16 US US10/514,386 patent/US20060094715A1/en not_active Abandoned
- 2003-05-16 EP EP03725415A patent/EP1503764B1/en not_active Expired - Lifetime
- 2003-05-16 CA CA2485600A patent/CA2485600C/en not_active Expired - Fee Related
- 2003-05-16 AT AT03725415T patent/ATE454153T1/en active
- 2003-05-16 ES ES03725415T patent/ES2339234T3/en not_active Expired - Lifetime
- 2003-05-16 DK DK03725415.8T patent/DK1503764T3/en active
- 2003-05-16 AU AU2003227949A patent/AU2003227949B2/en not_active Ceased
- 2003-05-16 WO PCT/GB2003/002134 patent/WO2003097065A1/en not_active Application Discontinuation
-
2005
- 2005-06-24 HK HK05105291.0A patent/HK1072012A1/en not_active IP Right Cessation
-
2009
- 2009-01-06 AU AU2009200050A patent/AU2009200050B2/en not_active Ceased
- 2009-02-17 US US12/372,592 patent/US8829028B2/en not_active Expired - Fee Related
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859683A (en) * | 1988-02-04 | 1989-08-22 | Rorer Pharmaceutical Corporation | Certain benzoxepins and their pharmaceutical compositions and methods |
US5591749A (en) * | 1991-03-07 | 1997-01-07 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 -antagonists |
US5196547A (en) * | 1991-03-07 | 1993-03-23 | G. D. Searle & Co. | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5219850A (en) * | 1991-03-07 | 1993-06-15 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5434161A (en) * | 1991-03-07 | 1995-07-18 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5604239A (en) * | 1991-03-07 | 1997-02-18 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5137893A (en) * | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US20030045452A1 (en) * | 1991-12-21 | 2003-03-06 | Smithkline Beecham Plc | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
US20020128172A1 (en) * | 1991-12-21 | 2002-09-12 | Smithkline Beecham Plc | Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5726187A (en) * | 1992-10-16 | 1998-03-10 | Smithkline Beecham Plc | N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists |
US6331401B1 (en) * | 1992-12-24 | 2001-12-18 | Synaptic Pharmaceutical Corporation | Uses of the 5-HT4 receptor |
US6127379A (en) * | 1993-02-01 | 2000-10-03 | Smithkline Beecham P.L.C. | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
US20020019386A1 (en) * | 1993-05-22 | 2002-02-14 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
US5872134A (en) * | 1993-05-22 | 1999-02-16 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
US20050149580A1 (en) * | 1994-05-06 | 2005-07-07 | Ryuichi Hattori | Data processing apparatus and network system that outputs quality of service information to a user |
US6100339A (en) * | 1994-11-21 | 2000-08-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Curable resin and resin composition comprising the same |
US6002009A (en) * | 1995-03-14 | 1999-12-14 | Boehringer Ingelheim Italia, S.P.A. | Di-substituted 1,4-piperidine esters and amides having 5-HT4 antagonistic activity |
US5929089A (en) * | 1995-11-09 | 1999-07-27 | Synthelabo | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-Ht4 or H3 receptor ligands |
US5990159A (en) * | 1996-02-15 | 1999-11-23 | Janssen Pharmaceutica, N.V. | Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
US6331631B1 (en) * | 1996-09-11 | 2001-12-18 | Smithkline Corporation P.L.C. | Preparation of 1-butyl-4-piperidinylmethylamine |
US6255319B1 (en) * | 1997-04-18 | 2001-07-03 | Sanofi-Synthelabo | 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as 5-ht4 receptor ligands |
US20040192911A1 (en) * | 1998-07-16 | 2004-09-30 | Smithkline Beecham P.L.C. | Process for the preparation of an indole derivative |
US6583294B2 (en) * | 1998-07-16 | 2003-06-24 | Smithkline Beecham P.L.C. | Process for the preparation of an indole derivative |
US6946565B2 (en) * | 1998-07-16 | 2005-09-20 | Smithkline Beecham Plc | Process for the preparation of an indole derivative |
US20030032640A1 (en) * | 2000-08-08 | 2003-02-13 | Buxton Philip Christopher | Novel composition |
US20060057218A1 (en) * | 2000-08-08 | 2006-03-16 | Smithkline Beecham P.L.C. | Novel composition |
US6624162B2 (en) * | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
US20040034226A1 (en) * | 2001-10-22 | 2004-02-19 | Chikara Uchida | Imidazopyridine compounds as 5-HT4 receptor modulators |
US20030092699A1 (en) * | 2001-10-22 | 2003-05-15 | Chikara Uchida | Imidazopyridine compounds as 5-HT4 receptor modulators |
US6979690B2 (en) * | 2002-01-07 | 2005-12-27 | Pfizer Inc. | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators |
US20050075335A1 (en) * | 2002-02-14 | 2005-04-07 | Buxton Philip Christopher | Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation |
US20040122043A1 (en) * | 2002-09-20 | 2004-06-24 | Pfizer Inc | Imidazopyridine compounds as 5-HT4 receptor agonists |
US7012080B2 (en) * | 2002-09-20 | 2006-03-14 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
DK1503764T3 (en) | 2010-05-10 |
AU2003227949A1 (en) | 2003-12-02 |
EP1503764A1 (en) | 2005-02-09 |
ES2339234T3 (en) | 2010-05-18 |
US8829028B2 (en) | 2014-09-09 |
CA2485600A1 (en) | 2003-11-27 |
EP1503764B1 (en) | 2010-01-06 |
AU2009200050A1 (en) | 2009-02-05 |
GB0211230D0 (en) | 2002-06-26 |
HK1072012A1 (en) | 2005-08-12 |
AU2009200050B2 (en) | 2010-11-11 |
US20090169545A1 (en) | 2009-07-02 |
ATE454153T1 (en) | 2010-01-15 |
WO2003097065A1 (en) | 2003-11-27 |
AU2003227949B2 (en) | 2008-12-11 |
CA2485600C (en) | 2010-04-20 |
DE60330857D1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021282467B2 (en) | AR+ breast cancer treatment methods | |
Frishman et al. | Serotonin and the heart | |
Dobrydnjov et al. | Postoperative pain relief following intrathecal bupivacaine combined with intrathecal or oral clonidine | |
US6835740B2 (en) | Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride | |
US8829028B2 (en) | 5-HT4 receptor antagonists for the treatment of heart failure | |
KR20100039292A (en) | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | |
EP0710479B1 (en) | Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine | |
WO2004067003A1 (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension | |
JP2010522751A (en) | Combination therapy for the treatment of lower urinary tract symptoms | |
JPH11510828A (en) | Method for treating vomiting and central nervous system disorders using optically pure (+) norcisapride | |
PT2370070E (en) | Pimobendan for use in the treatment of hypertrophic cardiomyopathy in cats. | |
EP2716302A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
Scrogin et al. | Central methysergide prevents renal sympathoinhibition and bradycardia during hypotensive hemorrhage | |
US10272075B2 (en) | Method and composition for treating an alpha adrenoceptor-mediated condition | |
Wohlreich et al. | Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine | |
Pügge et al. | Exercise training normalizes renal blood flow responses to acute hypoxia in experimental heart failure: role of the α1-adrenergic receptor | |
Qvigstad et al. | Carvedilol blockade of α1-and β-adrenoceptor induced inotropic responses in rats with congestive heart failure | |
Suzuki et al. | Effects of the AT1‐receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure | |
Kitzman | Why is diastolic heart failure in older patients the cardiologist's enigma | |
Abbott et al. | Antiarrhythmic drugs | |
EP1696896A2 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
Bleske et al. | Carvedilol: therapeutic application and practice guidelines | |
Górska et al. | Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats | |
JPH0827029A (en) | New medicine use of 5ht1 agonist | |
de Vries | 5-Hydroxytryptamine Receptors Mediating Carotid and Systemic Haemodynamic Effects: The Relation to Acute Antimigraine Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDINNOVA AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEVY, FINN OLAV;REEL/FRAME:016663/0659 Effective date: 20050801 |
|
AS | Assignment |
Owner name: MEDINNOVA SF, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEVY, FINN OLAV;REEL/FRAME:017608/0687 Effective date: 20030515 |
|
AS | Assignment |
Owner name: MEDINNOVA AS, NORWAY Free format text: CHANGE OF NAME;ASSIGNOR:MEDINNOVA SF;REEL/FRAME:017608/0947 Effective date: 20040430 |
|
AS | Assignment |
Owner name: BIO-MEDISINSK INNOVASJON AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDINNOVA AS;REEL/FRAME:017624/0506 Effective date: 20050526 |
|
AS | Assignment |
Owner name: SERODUS AS, NORWAY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIO-MEDISINSK INNOVASJON AS;REEL/FRAME:021975/0236 Effective date: 20080911 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |